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ABSTRACT 
Background: Recurrent syncope is a common clinical problem. Head up tilt (HUT) testing 
reproduces reflex syncope in controlled laboratory settings. Echocardiographic monitoring of 
parameters including change in fractional shortening (FS) have been used to identify false 
positive responses on HUT testing. We assessed predictors of recurrent syncope in patients with 
unexplained recurrent syncope undergoing HUT testing. 
Methods: This study is a prospective follow up of a cohort of patients undergoing HUT for 
unexplained recurrent syncope, with additional monitoring of echocardiographic left ventricular 
(LV) dimensions/ FS during HUT. The study was performed from Jan 2010 to Jan 2011.  
Results: Sixty patients underwent HUT testing. Mean age was 46 ± 15 years and median 
duration of symptoms was 12 months (IQR 6 to 24 months). Thirty five (58.3%) patients had 
positive HUT response. Mean time to syncope was 31.5± 6.9 minutes. At the end of the tilt 
phase, FS in the HUT positive group increased significantly from baseline (32.4±0.68% to 
37.5±0.64 %, p< 0.001), while FS did not change significantly in the HUT negative group. Ten 
(16.7%) patients had recurrent syncope on follow up. During HUT test, achieving a maximum 
heart rate of ≥ 108 beats per minute was predictive of recurrent syncope [OR 8.62 (1.002-73.84), 
p=0.049] 
Conclusions: In patients with a positive response on HUT testing, there is a significant increase 
in LV FS during tilt as compared to those with a negative response. Patients who have recurrence 
of syncope on follow up tend to have higher peak heart rate attained during HUT. Hence peak 
heart rate attained during HUT testing can be used to identify patients at high risk of recurrence 
of syncope. 
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INTRODUCTION 
Recurrent syncope is a commonly encountered clinical problem and remains a 
major diagnostic as well as therapeutic challenge in any clinical setting. Even though only a 
small percentage of patients experiencing syncope in the community present themselves to a 
hospital, syncope still accounts for 1% of presentations in European acute medical care settings 
(1)(2) (Figure 1). In order to prognosticate or risk-stratify patients presenting with syncope, two 
major aspects ought to be considered: first the risk of mortality and major adverse cardiac events 
and second the risk of recurrent syncope and consequent injury/ trauma. Syncope especially 
when recurrent has a pervasive detrimental influence on the quality of life of patients. Syncopal 
burden has inverse correlation with quality of life (3).  Recurrent syncopal episodes are 
associated with orthopedic fractures and soft tissue injury in 12% of patients (4). While a 
detailed preliminary evaluation including an exhaustive clinical history, physical examination 
and a resting ECG will diagnose the underlying cause of syncope in 23 - 50% of subjects 
presenting with syncope, the remaining patients will require further risk stratification and 
additional diagnostic testing (5). 
Reflex (neurally mediated) syncope, also known as neurocardiogenic syncope continues 
to be the leading cause of syncope in any clinical setting. In contemporary clinical practice, tilt 
testing remains the singular investigation that is available to the clinician, in order to demonstrate 
the propensity for reflex syncope in patients presenting with otherwise unexplained syncope. 
Head up tilt (HUT) testing reproduces reflex syncope in controlled laboratory settings and this 
has been shown to correlate with the patients original symptoms. Even in patients estimated to 
have a high risk of major adverse cardiac events and in those with clinical markers indicative of 
underlying brady-arrhythmia, HUT testing has been demonstrated to be of diagnostic value when 
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an underlying cardiovascular etiology has been ruled out by focused and comprehensive 
investigations. Since 1986 when HUT testing was originally introduced, the tilt protocol has 
evolved through multiple modifications. Studies have looked at the effect of modifying the 
duration of the pre-tilt supine phase, duration of tilt phase, angle to which the table is tilted and 
different drugs for pharmacological challenge, in order to arrive at an optimal protocol (6). HUT 
testing has become widely adopted in clinical practice, especially in the diagnostic evaluation of 
reflex syncope. However the absence of a “gold standard” for diagnosing syncope has made the 
sensitivity of HUT test questionable. 
Apparently healthy subjects without any indication of cardiovascular disease may have a 
positive response to tilt testing (7) (8). The false positivity rate of HUT test is influenced both by 
patient characteristics including age and protocol characteristics including duration, angle of tilt 
and use of provocative drugs (9) (10). Studies comparing patho-physiological changes during 
positive tilt testing in healthy volunteers and patients presenting with reflex syncope have shown 
that the hemodynamic as well as humoral mechanisms leading to syncope are qualitatively and 
quantitatively different in these two groups. In patients presenting with reflex syncope, studies 
show that there is accelerated peripheral venous pooling as indicated by a more marked and 
exaggerated decline in left ventricular end diastolic dimension (LVEDD) as compared to HUT 
positive healthy volunteers. These patients were also demonstrated to have higher left ventricular 
(LV) contractility as indicated by values of fractional shortening (FS) associated with elevated 
levels of epinephrine (11).  
Hence we postulated that, echocardiographic parameters such as FS and decrease in 
LVEDD may help in identifying a false positive group of patients in those undergoing HUT 
testing for unexplained syncope. We also postulated that these echocardiographic parameters 
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may help in assessing the risk of recurrence of syncope, thereby helping to direct therapy and 
interventions in order to limit recurrences and prevent physical injury and morbidity from 
syncope.  
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AIMS AND OBJECTIVES 
Aim: 
1. The aim of the study was to characterize the clinical, hemodynamic and 
echocardiographic variables including LV contractility during tilt in patients with 
unexplained recurrent syncope undergoing HUT test and to correlate the same with 
clinical outcomes 
Objectives: 
1. To determine the LV contractility during tilt in patients with unexplained recurrent  syncope 
undergoing tilt testing by measuring the LV end diastolic and systolic dimensions and FS, 
using echocardiography during tilt 
2. To determine if change in FS during HUT test will predict recurrence of syncope during 
follow up 
3. To determine other significant predictors of recurrent syncope in the study population 
4. To determine the predictors of positive response to HUT test 
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REVIEW OF LITERATURE 
Syncope is a common presenting complaint in any clinical setting. Clinically syncope can 
be defined as a transient loss of consciousness caused by cerebral hypoperfusion, the hallmarks 
of which include abrupt onset, brief duration, and spontaneous complete recovery without 
residual neurological deficits. The term pre-syncope is commonly used in clinical parlance to 
depict a spell that is similar to the prodrome of syncope but which is not followed by loss of 
consciousness. Questions have been raised as to whether the patho-physiology of pre-syncope is 
same as that of syncope.  In the 17th century John Hunter, a surgeon, documented the 
vasodepressor manifestations of syncope in a patient undergoing phlebotomy. In the 18th century, 
researchers including Foster identified vagally mediated cardio-inhibition as the causative 
mechanism underlying syncope. Lewis coined the term ´vasovagal syncope´ (12). 
The prognosis of patients with syncope is not homogenous. Syncope can be benign. Less 
commonly syncope can be a harbinger of sudden cardiac death. Even though the cause is benign, 
recurrent syncopal episodes result in substantial morbidity. Syncope can cause injury. Syncope 
causes significant anxiety among subjects and their relatives, resulting in substantial functional 
limitation comparable to the level of debilitation seen in many chronic illnesses. Syncope poses a 
huge burden on the society in terms of medical, social, and economic impact. In the United 
States alone more than one million patients are worked up for syncope every year. Different 
registries have shown that that upto 5% of emergency department consultations and upto 6% of 
hospitalizations are for evaluation of syncope in Western populations (13).  In a recent European 
series the median duration of hospitalization was 5.5 days (2). The most commonly encountered 
form of syncope is vasovagal syncope (common faint). It is also known as neurocardiogenic 
syncope or neurally mediated syncope. Proven as well as efficacious treatment for 
 neurocar
managem
for preve
only subo
as episod
 
      Figure 
 
A
by globa
which le
mediated
syncope.
diogenic syn
ent of recur
nting recurr
ptimal. Dru
ic nature of 
1.Syncope eve
n etiologic c
l cerebral hy
ads to sync
 bradycardia
 Secondly, c
cope rema
rent of vaso
ence of sync
g trials for 
neurocardio
nts/ visits per 
lassification
poperfusion
ope, as sho
 which is al
ardiovascul
G
9.3
Ge
18.1‐ 3
ins elusive. 
vagal synco
ope, the cho
this purpose
genic synco
1000 patient-y
 system for
.  There ar
wn in tabl
so known a
ar causes a
E
0.7 p
enera
 per 1000
neral p
9.7per 1
There are o
pe. Even tho
ice of thera
 have been m
pe and by th
ears [data from
 syncope ha
e three mai
e 1. The co
s cardio-inh
lso contribu
D
er 1000
l pract
 patient 
opula
000 pati
nly limited
ugh multip
py is mostly
ostly hamp
e heterogen
 (14)] ED Em
s been prop
n causes of 
mmonest u
ibitory type 
te to the eti
ice 
years
tion
ent years
 therapeutic
le drugs hav
 empirical a
ered by the
eity of the s
ergency depar
osed (15). S
transient lo
nderlying c
of reflex (ne
ology, inclu
 options fo
e been evalu
nd its effica
 sporadic as
tudy popula
tment  
yncope is ca
w cardiac o
ause is a r
urally medi
ding arrhyt
8 
r the 
ated 
cy is 
 well 
tion. 
used 
utput 
eflex 
ated) 
hmia 
9 
 
and structural cardiac diseases. Yet another cause is inadequate venous return, which in turn may 
be due to dehydration or venous stagnation in the lower limbs. 
 
Table 1. Etiological Classification of Syncope (15) 
Reflex Syncope 
- Vasovagal or neurocardiogenic 
- Situational (e.g. cough, micturition) 
- Carotid Sinus Hypersensitivity 
- Syncope without obvious triggers or non-typical presentations 
 
Syncope resulting from Orthostatic Hypotension 
- Medications causing Orthostatic Hypotension 
- Primary Autonomic Failure 
- Secondary Autonomic Failure 
- Volume Depletion 
 
Cardiovascular Syncope 
- Arrhythmias: bradycardia and tachy-arrhythmias 
- Structural Cardiovascular Diseases: Valvular heart diseases, aortic dissection, acute myocardial 
infarction, hypertrophic cardiomyopathies, cardiac tumors,  cardiac tamponade, coronary artery 
anomalies, pulmonary hypertension and pulmonary embolism 
 
Pathophysiology of Neurocardiogenic Syncope 
  Blood pressure is regulated at the central nervous system (CNS) level by a 
complex mechanism. This includes CNS processing of both afferent and efferent signals. The 
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impulses relayed from the aortic and carotid sinus baroreceptors continually regulate the arterial 
blood pressure levels. These neural impulses are carried in the vagus nerve and glossopharyngeal 
nerve respectively and they relay to the CNS. These neural impulses are processed in the the 
nucleus tractus solitarius. This will result in inhibition of efferent sympathetic outflow and 
augmentation of the efferent vagal outflow (12). A fall in the arterial blood pressure leads to an 
augmentation of the sympathetic outflow and suppression of vagal output. Thus this neural reflex 
system modulates the balance between the sympathetic and parasympathetic system thereby 
regulating the blood pressure levels.  
In addition to the above mentioned reflex system there are cardiopulmonary 
baroreceptors which are located in the ventricular walls and in the vasculature. These 
baroreceptors also regulate the sympathetic outflow (16). Ventricular stretch mediated by 
increased filling pressures is the main stimulus for these receptors. Based on the underlying 
pathogenesis, a classification system for neurocardiogenic syncope has been proposed. 
Neurocardiogenic syncope is classified as ‘vasodepressor type’ if hypotension occurs due to a 
loss of the vasoconstrictor sympathetic tone and ‘Cardio-inhibitory’ when bradycardia or 
asystole occurs. Neurocardiogenic syncope is classified as mixed if both these mechanisms 
contribute. 
  
On assumption of erect posture a number of compensatory physiologic changes involving 
the sympathetic and parasympathetic reflex systems come into effect. When a patient assumes 
upright posture these is pooling of more than half a liter of blood in the lower extremities.  Thus 
reduced venous return will decrease the filling pressure in the ventricle. Hence the mean arterial 
pressure as sensed by the aortic arch and carotid sinus drops (12). This would trigger a 
compensatory increase in the afferent neural activity; as a result there are increased sympathetic 
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impulses relayed to the cardiac and vascular structures. This cascade of events will ultimately 
result in peripheral vasoconstriction, increased inotropic and chronotropic response. As a result 
the mean arterial blood pressure is maintained and the subject does not faint. 
While much research has gone into delineating the patho-physiology of neurally 
mediated syncope, not all aspects have been explained adequately thereby rendering the 
diagnosis and treatment of this common condition difficult. Hence therapies targeting different 
aspects of the purported patho-physiologic mechanism of syncope have not yielded optimal 
results. The most widely implicated patho-physiological mechanism causing neurally mediated 
syncope is the Bezold–Jarisch reflex (16,17). Bezold–Jarisch reflex is a neurocardiogenic reflex 
that is triggered by venous pooling in the lower limbs especially in dehydrated subjects. This 
results in decrease in ventricular volume and cardiac filling pressures. Compensatory 
baroreceptors reflex comes into play and resultant sympathetic discharge mediates increase in 
contractility of the left ventricle. Consequently mechanoreceptors that are activated by changes 
in wall tension located in the left ventricle wall are activated inappropriately. The C- fiber 
mediated afferent signals are relayed through the vagus nerve to the CNS. That mediates a reflex 
decrease in the sympathetic outflow to the vasculature and the cardiac structures, and inverse 
changes occur in parasympathetic activity. Marked vasodilatation occurs. This is accompanied 
by bradycardia and hypotension. These changes are the hallmarks of the loss of consciousness 
that characterize neurally mediated syncope. These changes are promptly reversed once the 
subject assumes supine posture. Thus we may conclude that neurally mediated syncope mainly 
takes place in predisposed patients due to excess lower limb venous pooling that leads to a 
sudden drop in venous return leading to inappropriate activation of LV mechanoreceptors 
thereby causing bradycardia and hypotension culminating in syncope. 
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Mechanoreceptors are present at multiple other sites including the urinary bladder, 
rectum, and respiratory organs. It has been postulated that abrupt activation of these receptors 
groups during micturition, defecation or coughing transmits afferent signals to the CNS thereby 
triggering a reflex mediated syncope. This is considered to be the maladaptive mechanism 
underlying situational syncope. 
In humans Bezold–Jarisch reflex, has been implicated in the pathogenesis of reflex 
syncope largely based on indirect evidence. In patients with reflex syncope, during tilt, a surge in 
catecholamine levels has been demonstrated occurring just prior to loss of consciousness (18). 
However, exaggerated activation of the sympathetic system prior to syncope has not been 
demonstrated across studies in a consistent manner. In human studies, recording of neural 
impulses in peroneal nerve fibers using microelectrodes has demonstrated an increase in 
sympathetic neuronal traffic in the presyncopal phase, followed by a sudden withdrawal of 
sympathetic neuronal activity just prior to onset of syncope. Echocardiographic studies have 
demonstrated decrease in the LVEDD and end diastolic volume in syncopal subjects during tilt 
testing (19,20). 
However neurally mediated syncope in humans, cannot be entirely attributed to the 
Bezold–Jarisch reflex mechanism. This point has been illustrated by the fact that a pure 
vasodepressor response without a drop in heart rate has been demonstrated during tilt induced 
neurocardiogenic syncope in post heart transplant patients (12). Neural reflex mechanism is 
effectively ruled out in this case as cardiac afferent and efferent pathways are denervated in a 
transplanted heart. This partly explains the lack of bradycardia in these patients. Hence multiple 
triggers beyond those described in the Bezold–Jarisch reflex are likely to be operative in neurally 
mediated syncope. However skeptics have argued that response may be just a type 3 (as per 
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VASIS classification) also known as pure vasodepressor response occurring in cardiac transplant 
recipients and not due to the surgical cardiac denervation alone (21)(22,23). EEG monitoring 
during HUT has shown increased activity in the left cerebral hemisphere in subjects developing 
syncopal response on tilt test. This lateralization occurs prior to the onset of loss of 
consciousness and accompanies the drop in heart rate and blood pressure and onset of symptoms. 
Hence the left cerebral hemisphere may be a part of the neural circuit that mediates vasovagal 
syncope (24). 
Studies have indicated that multiple neurotransmitters and neuro-modulators influence 
the pathogenesis of neurally mediated syncope. These neurotransmitters include serotonin (25), 
adenosine, and opioids (26). Emotional stress may precipitate reflex syncope. The neural reflex 
mechanism underlying vasovagal syncope may be modulated by impulses from the 
hypothalamus and forebrain. Prior to vasodepressor syncope a surge in the levels of  beta 
endorphins have been demonstrated (27). Opioid µ receptor antagonists have been demonstrated 
to augment the cardiac baroreflex mediated stimulation of sympathetic pathway (28). The µ 
receptor antagonist naloxone has not been successful in aborting syncope during HUT (29). 
Not only central neurotransmitters but also peripheral neuronal triggering mechanisms 
other than those typified by the Bezold–Jarisch reflex may play a role in the pathogenesis of 
reflex syncope. Intravenously administered adenosine has been shown to trigger sympathetic 
afferent activity (30). This fact underlies the use of adenosine as a pharmacological challenge 
during tilt testing. However adenosine induced tilt test response has shown no correlation with 
the recurrence rate of syncope or with the mechanism of spontaneous syncope as demonstrated 
by studies using implantable loop recorders (31). Pharmacological challenge with isoproterenol 
has been shown to counter the decrease in LVEDD that occurs in patients with reflex syncope 
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during tilt testing (32). Thus a decrease in ventricular volume leading to triggering of LV 
mechanoreceptors may not an imperative step in the pathogenesis of reflex syncope. Also the 
hemodynamic responses preceding syncope are distinctly different in those with passive tilt 
induced syncopal response as compared to those with a positive response to tilt testing with 
isoproterenol pharmacological challenge (33). Just prior to the onset of loss of consciousness, 
patients in the isoproterenol challenged tilt test group had a higher heart rate and cardiac output 
as compared to patients with passive tilt induced syncopal response. This heterogeneity in the 
hemodynamic response in these two groups of patients suggests differences in the syncopal 
triggering mechanisms in these groups. 
The sudden fall in peripheral vascular resistance that is one of the final steps in the 
pathophysiology of reflex syncope, has been investigated by many groups. One postulate is that 
the peripheral vasodilatation is a passive mechanism mediated by a withdrawal of sympathetic 
activity. However multiple studies have demonstrated the presence of a sympathetic mediated 
active vasodilatation in humans. This active skeletal muscle vasodilatation may be initiated by 
changes in sympathetic tone mediated by cholinergic vasodilator nerves or by release of nitric 
oxide (NO). Patients with positive response to HUT test have been shown to have excessive 
metabolism of NO (34). Also the presence of NO as a peripheral neurotransmitter has been 
demonstrated in skeletal muscles. 
Thus it can be concluded that the Bezold–Jarisch reflex is one of the many causative 
pathways of reflex syncope. 
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History and Physical Examination 
Reflex syncope can be precipitated by a number of triggers including prolonged standing, 
strenuous exertion on a hot day, emotional stress, sight of blood and excessive physical pain. 
Patient may complaint of prodromal symptoms including lethargy, giddiness, sweating, dimness 
of vision, heaviness of head and nausea. Transient clinical signs that may be demonstrated at this 
stage include facial pallor, dilatation of pupils and flushing. This prodromal phase may be very 
brief or may last up to a few minutes prior to the actual occurrence of loss of consciousness. 
Some patients successfully abort the syncopal episode by recognizing this prodromal phase and 
assuming a supine position or by employing certain “physical counter pressure maneuvers”.  
However, a minority of patients especially elderly subjects do not have a prodrome preceding the 
syncopal episode hence they are at risk of physical injury resulting from abrupt loss of postural 
tone (35). 
 Syncope is characterized by short duration of loss of consciousness, which may last for 
up to five minutes. Elderly patients have a number of atypical features including lack of 
prodromal symptoms, longer duration of syncope and post spell confusion which may last up to 
ten minutes or rarely longer. Syncope on occasions can have atypical features including jerky 
seizure-like movements. Some researchers refer to this as “convulsive syncope” (36). When the 
patient regains consciousness, he/ she may experience lethargy or fatigue. Patient may appear 
pale and at times can have profuse sweating after the spell. Post spell confusion is in favor of 
seizure disorder. Recovery from syncope is characteristically abrupt, and without any residual 
neurological deficits. A simple questionnaire has been used to differentiate syncope from 
seizures with a high degree of sensitivity as well as specificity (37). Questions enumerating 
clinical history from this point score system have been included in our questionnaire. 
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A focused and exhaustive clinical evaluation should also include an electrocardiogram, 
and a detailed drug history to identify the use of any proarrhythmic drugs including the use of 
Class IA and IC anti-arrhythmic medications. If available, bystanders who witnessed the 
syncopal spell should be interviewed to identify etiological markers. Jerky limb movements and 
tonic posturing may be associated with both cardiac and neurological causes of syncope. 
Absence of a prodrome is a clinical marker of cardiac arrhythmia. Rarely absence of prodromal 
symptoms may be indicative of dysautonomia (35). Recurrent syncope presents sporadically. It is 
not clear why syncopal spells occur in clusters, interspaced by relatively long asymptomatic 
periods. Hence compliance with drugs and other therapy becomes an issue. Family history of 
sudden cardiac death is important to elicit. History of exertional syncope points to structural 
heart disease especially those with fixed cardiac output. 
A detailed clinical examination including postural blood pressure response should be 
documented in every patient. This includes a cardiovascular and neurologic examination in all 
patients. The clinical examination may provide clues to the etiological diagnosis including the 
presence of LV dysfunction, pulmonary arterial hypertension, valvular heart disease, 
hypertrophic cardiomyopathy and other structural cardiac diseases. Carotid bruits point to 
underlying carotid artery stenosis. In the majority of patients, a detailed clinical history and 
physical examination has high efficacy in identifying the etiology of syncope, though the 
underlying pathology of syncope remains unidentified in about 40% of patients (38).  
 
Investigating Syncope 
 In cases where there is an underlying conduction disturbance or arrhythmia, ECG 
provides vital clues to the diagnosis. A number of conditions like sick node dysfunction, 
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atrioventricular conduction blocks, presence of an accessory pathway, channelopathies including 
Long QT Syndrome and Brugada syndrome, causing syncope, may be diagnosed on the ECG. 
The ECG may suggest a diagnosis of arrhythmogenic right ventricular dysplasia (ARVD).  
Frequent ventricular ectopics or a short run of nonsustained ventricular tachycardia especially in 
patients with underlying structural cardiac disease increases the likelihood of an underlying 
arrhythmic cause of syncope. However since the underlying arrhythmic episode is usually 
sporadic the diagnostic yield of a 12 lead surface ECG for this purpose may be low. 
A variety of options for ambulatory ECG monitoring is available to the clinician. The 
“gold standard” for diagnosing cardiac arrhythmia as the cause of syncope is ECG 
documentation of the arrhythmia coinciding with the patients’ symptoms. The singular factor 
that determines the device selection and duration of ambulatory monitoring is frequency of 
symptoms. Holter monitoring is widely available and is suitable for spells that recur on a daily 
basis. When the spells recur on a monthly basis an event monitor may be prefered. An 
implantable loop recorder is suitable for those with very infrequent symptoms. Implantable 
recorders can be used for up to 14 months and permits the clinician to correlate the patient’s 
symptoms with the underlying cardiac rhythm. Implantable loop recorders have a high diagnostic 
yield. These devices are able to diagnose up to 90% of patients presenting with unexplained 
recurrent syncope (39). The use of implantable loop recorders has revolutionized the 
management of syncope by providing insights into the pathophysiology of syncope in an 
individual patient and it is shown to be cost-effective (40). 
 Cardiac imaging including echocardiogram is indicated only in select patients with 
syncope. Echocardiogram is a indicated if underlying structural heart disease is suspected 
clinically (41). It may also be indicated if the clinical history, physical examination and ECG 
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have not yielded a diagnosis. Echocardiogram is an appropriate imaging technique to diagnose 
many underlying causes of syncope including valvular lesions, hypertrophic obstructive 
cardiomyopathy (HCM), pulmonary embolism, LV dysfunction and ARVD. When patients 
known to have ischemic heart disease or those at high risk for ischemic heart disease, present 
with unexplained syncope, further evaluation is indicated. When there is history of exertional 
syncope, exercise stress testing is indicated. During exercise stress testing, a hypotensive 
response or a failure of blood pressure to increase with exercise is of particular significance. This 
may point towards a diagnosis of HCM, high risk ischemic heart disease and autonomic failure. 
Exercise stress testing may also suggest the presence of catecholaminergic polymorphic 
ventricular tachycardia. A diagnosis of neurocardiogenic syncope or reflex syncope can be made 
in a patient presenting with a typical history in the absence of other plausible explanations for the 
syncopal episode (42). Further evaluation is indicated if the clinical features are atypical. 
 
 
Syncope in the Patient with an Apparently Normal Initial Evaluation 
 
After a detailed clinical evaluation and focused comprehensive investigations, if no 
cardiac disease is detected, it is likely that the syncopal episodes are not associated with 
increased mortality. In such a scenario the main objective of further evaluation is to identify the 
risk of physical injury and occupational risks from recurrence of syncope. For this purposes the 
AHA/ACCF has defined a “malignant episode of syncope” as a syncopal spell that occurs 
without any prodromal warning symptoms resulting in physical injury to self or causing property 
damage (41). Hence occupational groups like drivers and pilots presenting with syncope may 
require further detailed evaluation for medico-legal purposes. However deciding on further 
investigations, after an apparently normal initial evaluation, can be a difficult task as the yield of 
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many of these investigations are low. Even after the above mentioned investigations do not yield 
a diagnosis one should still actively consider alternative diagnoses like reflex syncope, carotid 
sinus hypersensitivity especially in elderly patients, arrhythmias including atrial and ventricular 
tachycardia.  
 
The Tilt Table Test 
Ever since it was introduced into clinical practice in 1986 by Kenny, et al, tilt testing has 
become the investigation of choice for evaluating patients presenting with unexplained recurrent 
syncope (7). HUT testing is primarily used for arriving at a diagnosis of reflex syncope, in a 
patient with a compatible history. Even though HUT testing has become widely acceptable as a 
feasible test for diagnosing reflex syncope, the clinical implications of a positive test response is 
still uncertain. The sensitivity, positive yield, and reproducibility of HUT testing reported in 
literature, vary widely (43), (44). The estimated sensitivity and specificity of HUT testing 
depends on patient factors as well as multiple factors in the tilt protocol (45). The sensitivity of 
HUT test is reported to vary from 26% to 80%, however these estimates may be inaccurate as 
there is no established “gold standard” for diagnosing neurocardiogenic syncope. The estimated 
specificity is about 90%; however it is well known that many healthy volunteers have a positive 
response on HUT (46).  Even when patients have a positive response on tilt testing, the 
hemodynamic changes and underlying pathophysiological mechanism may not be the same as 
those occurring during a spontaneous syncopal spell (as recorded by implantable loop monitors) 
(47).  
Table 2 illustrates the positive and negative results of HUT testing in adults. Table 3 
illustrates the reproducibility of tilt table testing. A positive response to initial HUT testing may 
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modify future responses to HUT testing. The reproducibility of HUT test (when a second tilt test 
is repeated after a variable time period ranging from hours to weeks) is 80% to 95% for an 
initially negative test response. However the reproducibility is much lower for an initially 
positive HUT response (30% to 90%). This has implications for the use of HUT testing in 
assessing the response to therapy. Indications for HUT testing are enumerated in Table 4. In 
subjects presenting with unexplained recurrent syncope, if the initial work up is negative and the 
clinically estimated likelihood of the diagnosis being reflex syncope is high, little incremental 
diagnostic or prognostic information is obtained by performing a HUT test. The negative 
predictive value of tilt table test is low in an individual patient with a high pretest probability for 
reflex syncope. In patients presenting with unexplained syncope and physical injury resulting 
from syncope and for those in high risk occupations, further investigations are warranted when 
the tilt response is negative. A positive HUT test response does not predict the risk for recurrence 
of syncope in these patients. 
 
 
Table 2. Passive Head Up Tilt Testing in Subjects with Unexplained Syncope  
 
Study Total 
patients 
Positive 
result on 
HUT 
Controls Controls 
with 
positive 
HUT 
Tilt angle Tilt 
duration 
 n n (%) N n (%) degrees minutes 
Kerry et 
al(7) 
15 10 (67) 10 1(10) 40 60 
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Fitzpatrick 
et al(48) 
71 53 (75) 27 2 (7) 60 60 
Strasberg et 
al(49) 
40 15 (38) 10 0 60 60 
Raviele et 
al(50) 
30 15 (50) 8 0 60 60 
Abi Samra 
et al(51) 
151 63 (42) 15 0 60 20 
Almquist et 
al (52) 
15 4 (27) 18 0 80 10 
Grubb et 
al(53) 
25 6 (24) 6 0 80 30 
Pongiglione 
et al(54) 
20 4 (20) 0 - 90 15 
Shen et 
al(55) 
111 35(32) 23 2 (9) 70 45 
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Figure 2. Head Up Tilt table testing © N Engl J Med 2005;352:1004-10. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Reproducibility of the Initial Results of Tilt-Table Testing 
 
Study 
(Reference)   
 
Protocol for 
Tilt-Table Test 
Time between 
Tests 
Positive 
Reproducibility 
Negative 
Reproducibility 
n/n(%) n/n(%) 
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de Buitleir et al 
(56) 
80° tilt, 10-min 
duration 
 
5 min   8/14 (57)  16/17 (94) 
Brooks et al (57) 
 
70° tilt, 25-min 
duration 
 
1 d  
 
11/30 (37)  
 
 45/56 (80) 
 
Raviele et al (50) 
 
60° tilt, 60-min 
duration 
 
3 d  
 
10/14 (71) 
 
- 
Fitzpatrick et 
al(48) 
 
60° tilt, 60-min 
duration 
 
- 24/31 (77) 
 
- 
Blanc et al(58) 
 
60° tilt, 60-min 
duration 
 
7 d   8/13 (62) 
 
- 
Fish et al(59) 
 
Isoproterenol 
used 
 
30 min   14–18/21 (67–
86) 
 
- 
Chen et al (60) 
 
Isoproterenol 
used 
 
30 min  12/15 (80) 
 
 8/8 (100) 
 
Grubb et al (61) 
 
Isoproterenol 
used 
 
5 d  
 
13/14 (93)  
 
 6/7 (86) 
 
Sheldon et al 
(62) 
Isoproterenol 
used 
 
2 wk  
 
 23/26 (88)  17/20 (85) 
 
G. Foglia-
Manzillo (63) 
 
60º for up to 45 
min. 400 µg 
sublingual spray 
nitroglycerin 
 
13 days 12/33 (36) - 
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Table 4. Indications for Head Up Tilt Testing (64)(15) 
Definite indications 
Recurrent syncope in the absence of underlying cardiac disease or in the presence of organic 
cardiac disease, after cardiac causes of syncope has have been ruled out using appropriate 
investigations (Class I B) 
A single episode of unexplained syncope occurring in a high risk setting (occupational 
implications or trauma resulting from syncope) (Class I B) 
HUT testing is used for demonstrating the susceptibility to neurocardiogenic syncope to the 
patient (Class I C) 
Possible indications 
Differentiation between reflex and orthostatic hypotension syncope (Class IIa C) 
Differentiation between syncope with jerking movements and seizure disorders (Class IIb C) 
Evaluation of repeated inexplicable falls (Class IIb C) 
Evaluation of patients with frequent syncope and psychiatric disease (Class IIb C) 
Evaluation of recurrent syncope in patients with neurological disorders like dysautonomia  or 
peripheral neuropathy 
Evaluation of exertional syncope especially exercise stress testing does not reproduce the spell 
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Not indicated in 
HUT testing is not recommended for evaluation of response to treatment (Class III B) 
Isoproterenol HUT testing is contraindicated in patients with ischemic heart disease (Class III C) 
 
Head-up tilt testing using sublingual nitroglycerin (NTG) challenge 
 
HUT testing  augmented by sublingual nitroglycerin was advocated by an Italian group 
(65) in 1995 by addition to the standard Westminster protocol (48)(7) of a NTG provocation 
phase. The nitroglycerin-head-up tilt is more sensitive than the non-medicated passive tilt test 
(65), and it is simpler and is increasingly used across the world. Thus, the test consisted of the 45 
minute passive phase directly followed, if negative, by nitroglycerin administration with the test 
continuing for further 20 min. This protocol, although twice as sensitive as the passive tilt alone, 
is time-consuming and not well accepted by many cardiologists. From the available evidence, 
shortening the passive phase from 45 minutes to 20 minutes results in a significant reduction in 
the positive response rate. On the other hand, this was balanced by an increase in the positive 
responses during the provocation phase (Tables 5, 6). Thus, the final positivity rate of the test 
remained unchanged (6). A possible explanation is that nitroglycerin ensures the positive 
responses of the late passive phase of the test, besides including an additional number of drug-
induced positive responses. In fact, assuming similar conditions of tilt angle, drug and its dose, 
the number of positive responses during the provocation phase of the test is always greater after a 
shortened rather than after a conventional passive phase (Tables 5, 6). Furthermore, the reduction 
of the passive phase to 20 minutes was accompanied by a decrease in the so-called ‘exaggerated 
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responses’. Finally, it was found that the specificity of the test was not affected by the duration 
of the passive phase (Table 7). 
 
Stabilization phase 
If invasive maneuvers are avoided before the test, 5 minutes are sufficient for the patient 
to achieve a stable physical condition. 
 
Passive phase 
Tilt angle 
As previously shown (66), the best tilt angle is 60º 
  Passive phase duration 
For all the above-mentioned reasons that the optimal duration of the passive phase is 
considered to be 20 minutes. 
Drug Challenge/ provocation phase 
Multiple studies have evaluated testing protocols (table 6) using sublingual crushed 
nitroglycerin tablets at a dosage of 300 µg dosage. However significant individual variation in 
pharmacokinetics resulted, including differences in the mucosal absorption rate depending on the 
amount of saliva available. This was an important consideration in older patients. In many 
subsequent studies (table 5), a protocol using 400 µg nitroglycerine oral spray has been reported. 
This protocol has many advantages including a higher dose of nitroglycerine used, better 
pharmacokinetics, ease of administration and reduced time to syncope. This protocol imparts 
better sensitivity to the tilt testing while maintaining comparable levels of specificity. Using 
sublingual nitroglycerin tablets, the time to syncope was demonstrated to be 7±8 minutes (65). 
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This interval was reduced to 5 ± 4 minutes using nitroglycerin in the spray form (67) ((68). This 
finding underlies a recommendation to shorten the duration of test by cutting down on the 
duration of the provocation phase from 20 to 15 minutes. This reduction in the duration of the 
provocation phase does not seem to affect the sensitivity of the test (6). 
 
Interruption of tilt 
The tilt phase is terminated and the patient made supine when the following end points 
occur: First, at the end of the drug challenge stage if the patient remains asymptomatic (test 
negative). Second, if there is loss of consciousness (test positive). The test is deemed positive 
whenever loss of consciousness (that is, the reproduction of the patients’ presenting symptom of 
syncope) occurs in association with hypotension and/ or bradycardia, with sudden (<5 minutes) 
onset. This positive HUT response is considered to be analogous to the prototypical vasovagal 
syncope. Recommendations suggest that the tilt phase should be terminated just when syncope is 
initiated with loss of postural tone, rather than at the onset of hypotension. The response can be 
classified according to the VASIS recommendations. However for classification purposes the 
hemodynamic responses until the onset of syncope has to be taken into account. The subsequent 
bradycardia should not be used for classifying the response.  The tilt may also be terminated if 
there is a tardy onset, prolonged (>5 minutes) hypotension. This is an indication of orthostatic 
intolerance and is associated with minor symptoms usually. The clinical significance of this 
particular response is still debated. This response at times can be documented in healthy subjects 
also. However in patients with orthostatic intolerance without syncope, autonomic nervous 
system dysfunction cannot be ruled out (21). 
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Diagnostic Criteria for Tilt Testing (15) 
 In patients presenting with unexplained syncope, but without organic cardiac disease the 
induction of hypotension and/ or bradycardia with reproduction of syncope is diagnostic 
of reflex syncope  
 In patients without organic cardiac disease the induction of progressive hypotension is 
diagnostic of orthostatic hypotension 
 In patients without organic cardiac disease, the induction of reflex hypotension and/ or 
bradycardia without reproduction of syncope may be diagnostic of neurocardiogenic 
syncope 
 In patients with structural heart disease, first tachy/bradyarrhythmias and alternative 
cardiovascular causes of syncope should be reasonably ruled out before interpreting the 
positive tilt test result as diagnostic 
 If the subject has loss of consciousness without accompanying hypotension and/ or 
bradycardia, a diagnosis of psychogenic pseudosyncope may be considered 
 
Table 5. Results of tilt table testing potentiated by nitroglycerin sublingual spray 400 µg 
 
Study, year Patient 
nos 
Passive 
phase 
Duration 
(min) 
Passive 
phase 
positivity 
(%) 
NTG phase 
positivity 
(%) 
Total 
Positive 
response 
Exaggerated 
responses 
Natale, et al 
1998(69) 
33 20 4(12) 22(67) 26(78)  
Del Rosso, 
et al. 
1998(70) 
202 20 22(11) 119(59) 141 (70) 8 (4) 
Del Rosso, 69 20 7 (10) 36 (52) 43 (62) 3 (4) 
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et al. 
1999(71) 
Total 
passive 
phase 20 
min 
304 20 33 (11) 177(58) 210(69) 23 (8) 
Bartoletti, 
1999(67) 
84 45 15(18) 28(33) 43 (51) 18(21) 
Fogila 
Manzillo, et 
al. 1999(63) 
48 45 9 (19) 25 (52) 34 (71) 2 (4) 
Del Rosso, 
et al. 
2000(68) 
31 45 3 (10) 21 (68) 24(77) 2(6) 
Total 
passive 
phase 45 
min 
163 45 27 (17) 74 (45) 101 (62) 22(13) 
 
 
Table 6. Results of head-up tilt + use of nitroglycerin sublingual tablets 300 µg 
Study, year Patient 
number 
Duration of 
passive 
phase 
Passive 
phase 
positivity 
(%) 
NTG phase 
positivity 
(%) 
Total 
positive 
responses 
Exaggerated 
responses 
Raviele, et al. 
2000(72) 
71 20 9 (13) 26 (36) 35(51) 3(4) 
Raviele, et al. 
1995(65) 
235 45 59 (25) 60 (26) 119(51) 33 (14) 
Kurbaan, et al. 
1999(73) 
102 45 35 (34) 38 (37) 73 (72) - 
Total (only 55, 
65) 
337 45 94 (28) 98(29) 192 (57) 33 (14) 
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Table 7. Response to sublingual nitroglycerin challenge tilt table test in healthy controls 
Study, year 
 
 
Number of patients Age (Meanേ SD) 
 
HUT  protocol Positive response 
(%) 
Raviele, et al. 
1995 (65) 
35 54± 19 60º×45 + 20 min 
NTG 0.3 mg 
2(6) 
Aerts, et al. 1997 
(74) 
20 27± 4 70º×45 + 15 min 
ISDN 5 mg 
6 (30) 
Natale, et al. 1998 
(69) 
16 67± 9 70º× 20 + 15 min 
NTG 0.4 mg 
2 (12) 
Del Rosso, et al. 
1998(70) 
34 45±17 60º×20 + 25 min 
NTG spray 0.4 mg 
2(6) 
Ammirati, et al. 
1998(75) 
23 36 ± 12 60º×30 + 15 min 
ISDN 1.25 mg 
0 (0) 
Bartoletti, et al. 
1999(67) 
25 49 ± 17 60º×45 + 20 min 
NTG spray 0.4 mg 
1(4) 
Del rosso, et al. 
2000(68) 
47 52± 20 60º×20 + 20 min 
NTG spray 0.4 mg 
2(4) 
Raviele, et al. 
2000(72) 
30 44± 10 60º×20 + 20 min 
NTG 0.3 mg 
3 (10) 
Total  230   18(8) 
 
Classification of vasovagal syncope by the Vasovagal Syncope International Study 
(VASIS) in 1992 provided insight into the different types of vasovagal responses observed 
during tilt-induced syncope (76). This classification system has been extended to tilt testing with 
pharmacological challenge (70) (73). Based on the hemodynamic changes preceding syncope the 
positive response to HUT testing can be categorized into different subgroups. This classification 
system is useful both as a research tool and for directing medical therapy and interventions. This 
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system may be of use in making the choice of permanent pacing versus drug therapy for the 
treatment of recurrent reflex syncope. 
 
Table 8: Classification of reflex syncope induced by HUT table testing- the modified VASIS 
Classification (73) (76) 
Type Classification 
Type 1 or mixed Heart rate during syncope ≥ 40 beats per 
minute (bpm) or falls to < 40 bpm for < 10 
seconds ± asystole for < 3 seconds. BP always 
falls prior to heart rate. 
Type 2A or Cardioinhibitory Heart rate during syncope < 40 bpm for >10 
seconds but asystole for > 3 seconds does not 
occur. BP falls prior to heart rate. 
Type 2B or Cardioinhibitory with asystole Asystole for > 3 seconds occurs. Systolic BP 
falls to < 80 mm Hg at or after rapid fall in 
heart rate. 
Type 3  or Pure vasodepressor Heart rate does not fall > 10% from its peak at 
syncope. Fall in BP alone precipitates syncopal 
response. 
First exception — chronotropic incompetence. This subgroup of patients shows no tachycardia 
response during the tilt (i.e. maximum heart rate during tilt < 10% from the pre-tilt rate). 
However there is no hypotensive response. 
Second exception — excessive heart rate increase. These patients show an excessive heart rate 
rise both at the onset of the upright posture and during the entire duration of tilt, till prior to onset 
of syncope (i.e. heart rate greater than 130 bpm). 
 
Subsequently a classification system based on interpretation of the hemodynamic patterns 
during the pre-syncopal phase of the HUT test with and without drug challenge using sublingual 
nitroglycerin, has been proposed (21).  First type is the classic vasovagal syncope pattern: in the 
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pre-syncopal period, subjects had a rapid and full compensatory reflex adaptation to the upright 
posture. This lead to a stabilization of the blood pressure levels until abrupt onset of the reflex 
syncope took place at the end of tilt. Second type is the dysautonomic (vasovagal) syncope 
pattern in which steady-state adaptation to upright posture does not take place. This mal-
adaptation leads to a steady and progressive fall in the blood pressure levels till the occurrence of 
a typical vasovagal reaction. Third is the orthostatic intolerance pattern in which there was a 
progressive fall in the blood pressure levels, similar to that of the dysautonomic group, but this 
hypotensive response was not followed by vasovagal syncope. 
 
Complications and contraindications of tilt table testing 
Tilt table testing is generally considered to be safe. There has been no report of mortality 
during tilt testing. Few cases of ventricular tachycardia with the use of isoproterenol in patients 
with ischemic heart disease or sick sinus syndrome have been reported in literature (77).  
However, no life threatening adverse effects from the use of nitroglycerine have been reported. 
Minor adverse reactions are common with both these drugs. These include palpitations with the 
use of isoproterenol and headache with the use of nitroglycerine. Rarely arrhythmias including 
atrial fibrillation can be triggered during or following a positive HUT test. This usually is 
transient (78).  Despite the low risk involved in tilt testing, resuscitation equipment including 
defibrillators should be readily available in the HUT room. Caution should be exercised in 
patients with known arrhythmias, HCM, aortic stenosis and LV systolic dysfunction. 
 
 
 
33 
 
False Positive HUT Test and Use of Echocardiography during HUT test 
  Echocardiographic studies have provided insight into the pathogenesis of syncope 
during tilt testing. The loss of consciousness due to reflex syncope has been by convention 
attributed to the activation of LV mechanoreceptors, which in turn trigger the Bezold-Jarisch 
reflex. Peripheral venous pooling, sympathetic nervous system activation, as well as 
hypercontractility of a relatively empty left ventricle are the other potential triggers involved in 
this reflex pathway that mediates reflex syncope. Indirect evidence for the role of LV 
mechanoreceptors in pathogenesis of reflex syncope in humans is largely derived from studies 
demonstrating increased LV FS and decreased LV volumes in subjects with syncope and positive 
tilt testing (19). Studies using echocardiography during tilt testing show an accelerated rate of 
reduction of end-diastolic volume index as well as significant decrease in stroke volume index 
and ejection fraction in subjects presenting with reflex syncope as compared to healthy 
volunteers. This phenomenon is due to redistribution of blood to the peripheral venous system 
during tilt and an early parasympathetic effect on LV contractility (79).  
The incidence of false positive responses has been demonstrated to be a problem inherent 
in HUT test. This has led many investigators to opine that tilt testing should only be used to 
confirm a clinically based diagnosis (10).  
Even though tilt induced syncopal response can occur in healthy volunteers (false 
positive), the hemodynamic as well as humoral changes that accompany this response are 
qualitatively distinct from those of HUT positive patients who complaint of syncopal spells 
during normal daily activities (true positive). These distinct hemodynamic and humoral 
alterations are enumerated below (11).  
a) Time to Syncope: 
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This was about twice as long in HUT positive healthy volunteers as compared to 
HUT positive patients with neurocardiogenic syncope.  
b) Time to drop in blood pressure: 
The true positives had a drop in blood pressure as early as two minutes into the 
test accompanied, at the same time, by tachycardia, while in HUT positive healthy 
controls (false positive cases), these alterations were absent till about two minutes 
before the onset of symptoms. The normal controls did not demonstrate either of 
these characteristics.  
c) LV end-diastolic dimension: 
The pattern of peripheral venous pooling in the three groups (true positives, false 
positives and true negatives) was indirectly estimated by analyzing changes in 
LVEDD. During tilt, both HUT positive groups ( true positives and false 
positives) exhibited a progressive decline in LVEDD, significantly different from 
pre-tilt LVEDD value, while the HUT negative subjects (true negatives) 
demonstrated an initial decline that promptly stabilized (11)(19). There is more 
rapid and exaggerated peripheral pooling of intravascular volume in patients 
presenting with neurocardiogenic syncope. The hypotensive response and the 
abrupt reduction in peripheral venous return during HUT are indicative of an 
abnormality in vascular control. Studies have demonstrated impaired 
vasoconstrictor response in patients with neurally mediated syncope during HUT 
(80) and during dynamic leg exercise (81)(82).  
d) Fractional shortening: 
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In patients with true positive reflex syncope, it has been demonstrated that FS 
assessed by echocardiography, significantly increases throughout the HUT test to 
become, at 2 min before the end of HUT, statistically different from the false 
positive and true negative groups (11).  
e) Epinephrine levels: 
During HUT, patients with reflex syncope had a sixfold increase in the 
epinephrine levels as compared to the baseline value, accompanying the 
bradycardia and hypotension. This increase in epinephrine level was significantly 
more than the level of increase seen in patients with false positive HUT results 
(11).   
Monitoring of select echocardiographic parameters like LVEDD and FS to enhance the 
specificity and sensitivity of HUT testing for the diagnosis of neurally mediated syncope has 
been proposed (11). However this awaits controlled trials with larger numbers of patients. The 
population of HUT positive patients is heterogenous when classified in terms of LV contractility 
change during HUT test. It has been shown that LV hyper-contractility preceding syncope exists 
in about 50% of HUT positive patients (83). In the remaining patients without increase in LV 
contractility prior to the syncope, it could be that a mechanism other than Bezold Jarisch reflex 
may be underlying the syncope. Or else it could be that this group of patients may be false 
positive cases, behaving like the HUT positive normal volunteers in whom LV contractility does 
not increase before syncope.  
No correlation has been made between monitoring parameters like LVEDD and FS 
during HUT test and clinical outcomes. Moreover the findings of increased FS during HUT have 
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been questioned in some earlier studies (84). The use of echocardiography during HUT testing 
has been largely limited to research settings.  
We may conclude that the use of echocardiographic monitoring of select parameters 
during HUT provides valuable insight into the pathogenesis of neurally mediated syncope and 
these findings may have major clinical and prognostic implications. 
 
Electrophysiological study in Unexplained Syncope 
In patients presenting with syncope of unknown cause, recent studies show that positive 
yield with electrophysiology study (EPS) occur mainly in the subgroup of patients with structural 
cardiac disease (85). The ability of EPS to arrive at an etiological diagnosis for syncope is 
determined by the pre-test probability of the disease as well as the protocol used for the study. 
The advent of efficacious non-invasive electrocardiographic monitoring including prolonged 
monitoring has increased the diagnostic yield and in turn has diminished the prominence of EPS 
as a diagnostic test. In those presenting with syncope and bi-fascicular block, the high degree AV 
block may be transient. Hence it may not be picked up on routine 24 hour ambulatory Holter 
monitoring and, hence prolonged period of monitoring may be required to document it by ECG 
(86). In those subjects presenting with syncope associated with bi-fascicular block, an EPS has 
high sensitivity for diagnosing intermittent high degree AV block. However the negative 
predictive value of EPS is limited while evaluating intermittent AV block as the etiology of loss 
of consciousness. 
 EPS may help in risk stratifying syncope. The induction of a sustained ventricular 
tachycardia and presence of severe LV systolic dysfunction can predict a life-threatening 
syncopal episode. The nonexistence of these adverse prognostic indicators in turn predicts a 
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more favorable outcome. It can be concluded that EPS with programmed electrical stimulation is 
a test with high diagnostic and prognosticating value in those presenting with unexplained 
recurrent syncope in the presence of coronary artery disease and markedly depressed cardiac 
function. However the diagnostic efficacy of EPS is questionable in patients with dilated 
cardiomyopathy (4).  
The current ESC guidelines suggest the following: In patients presenting with syncope in 
the presence of concomitant ischemic heart disease, EPS is warranted when the initial work up 
indicates an underlying arrhythmia (15). In patients presenting with syncope and underlying 
bundle branch block, EPS is to be performed when noninvasive investigations have not yielded 
an etiological diagnosis. In patients with syncope preceded by abrupt onset short duration 
palpitations, EPS can be considered when noninvasive tests have not yielded the correct 
diagnosis. In patients with high risk occupations and in patients with a diagnosis of Brugada 
syndrome, ARVD or HCM presenting with syncope, EPS may be performed in a select subgroup 
of cases (15). 
 
Therapeutic Options in Reflex Syncope: 
Counter-pressure maneuvers 
With the paucity of data on the effectiveness of pharmacological data, non-
pharmacological therapy, including physical counter-pressure maneuvers are emerging as the 
preferred treatment of reflex syncope. Recent studies have shown that isometric physical 
counter-pressure maneuvers involving the legs including leg crossing, or of the arms including 
hand grip and arm tensing, may successfully counter the hypotensive phase of an impending 
neurally mediated syncope by inducing a significant BP blood pressure rise. This would allow 
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the subject to abort or delay the frank syncopal spell in many cases, thereby preventing injury 
(87) (88).  
 
Tilt training exercises 
Tilt training involves the patient assuming an enforced period of upright posture, at a 
prescribed angle. The duration of tilt is progressively increased till the prescribed time period is 
reached. In highly motivated young patients with recurrent syncope and/ or presyncope triggered 
by orthostatic challenge, tilt training may reduce or prevent the recurrence of syncope (89).  The 
main drawback of tilt training is the poor long term compliance as this requires high patient 
motivation. Many studies including randomized controlled trials have shown that tilt training 
may not be efficacious in preventing recurrence of syncope in patients undergoing repeat tilt 
table testing (90). 
Drug therapy 
Since Bezold- Jarisch reflex is known to be the major underlying pathophysiological 
mechanism of reflex syncope, the use of beta blockers may decrease the ventricular 
mechanoreceptor activation, by virtue of their negative inotropic effect in neurally mediated 
syncope. However the outcomes of multiple randomized control trials have not lent credence to 
this plausible hypothesis. The use of beta blockers may not be optimal in subtypes of reflex 
syncope in which mechanisms other than increased sympathetic activation are operational. Beta 
blockers may aggravate the bradycardia in carotid hypersensitivity syndrome. Majority of 
randomized trials with long term follow up have failed to prove the effectiveness of beta 
blockers in preventing recurrent syncope (91)(92). 
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Alpha receptor agonists including etilefrine and midodrine have been used in the 
management of neurally mediated syncope. Peripheral blood pooling due to failure to achieve 
adequate vasoconstriction of the peripheral blood vessels underlie many cases of neurally 
mediated syncope. Etilefrine, an alpha agonist vasoconstrictor, at a dose of 25 mg twice daily 
failed to reduce the frequency or time to recurrent syncope in a randomized clinical trial as 
compared to placebo (93). The major drawback with midodrine is the mulpile and frequent 
dosing. This limits long-term compliance in most patients (94). Alpha agonists may cause 
urinary retention, hence caution to be exercised in elderly male patients. Based on available data 
it may be concluded that long term drug treatment with alpha-agonists alone may not be of 
benefit in neurally mediated syncope. Also long-term becomes a problem in patients with 
sporadic symptoms. 
Paroxetine has been shown to be efficacious in the management of frequent recurrent 
syncopal episodes (95). Tough fludrocortisone is widely used there are no randomized trials in 
adults which show fludrocortisone to be efficacious. 
Dual Chamber pacing with rate drop algorithm 
Studies have yielded conflicting results on the efficacy of cardiac pacing in patients with 
recurrent syncope (96) (97). A recent meta-analysis has shown a non-significant 17% reduction 
in the recurrence of syncope by pooling data from multiple double-blind trials. There was an 
84% reduction in those trials where the control group did not have a pacemaker implantation, 
probably contributed to by a placebo effect (98). Different explanations for the suboptimal 
results with pacing have been offered. The most plausible one is that cardiac pacing may affect 
the cardio-inhibitory component of the vasovagal reflex; however pacing has no impact on the 
vasodepressor element of syncope. 
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MATERIALS AND METHODS 
Study design: 
This study is a prospective follow up of a cohort of patients undergoing tilt table testing 
for unexplained recurrent syncope in the absence of structural heart disease, with additional 
monitoring of echocardiographic LV dimensions/ FS during tilt table testing. The study was 
performed during a 13 month period from Jan 2010 to Jan 2011.  
 
Setting: 
The study was conducted at the department of Cardiology, Christian Medical College Hospital, 
Vellore. Patients were recruited from the Cardiology outpatient department as well as the 
Electrophysiology outpatient department. The patients were followed up till the end of the study 
period. Consecutive patients referred for HUT test were enrolled provided they met the inclusion 
and exclusion criteria. Oral questionnaire was administered by one of the investigators prior to 
the tilt test in all the cases. Patients were followed up during review consults. If the patient was 
not able to return for a review consult, then telephonic interview and follow up was performed. 
 
Subjects: 
Inclusion Criteria: 
 
1. At least two syncopal episodes, with minimum one episode in the last one year that 
remained unexplained in spite of a detailed history, comprehensive physical examination, 
12-lead ECG and echocardiography. 24 hour ambulatory Holter recording and 
electrophysiology study were performed if indicated. Neurology consultation was 
obtained if indicated. 
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2. Normal heart structure and function by echocardiographic criteria. 
 
Exclusion Criteria: 
 
1. Technically inadequate echocardiographic images/ window  
2. History of usage of drugs known to cause orthostatic hypotension at the time of tilt 
testing. For those patients on beta blockers, beta blockers needed to be interrupted two 
days prior to tilt table testing. 
 
Tilt Table Testing Protocol: 
After obtaining documentary informed consent from all participants in the study, the tilt 
table testing was performed in a quite dedicated room. The patient was fasting for 4 hours prior 
to the test. All medications that could interfere with tilt table testing including diuretics, 
vasodilators and beta blockers were withheld for at least 48 hours prior to the test. The HUT 
table testing was performed by using an electrically controlled tilt table with a foot board for 
weight bearing (Ausmedic supplies, Australia) and three safety straps across the bed to hold the 
patient in case of loss of consciousness. The heart rate was continuously monitored using a 3- 
lead ECG monitor. Radial intra-arterial blood pressure monitoring was performed during the test. 
Electrocardiographic and BP data were continuously displayed on a monitor (Hewlett Packard). 
We used a modification of the “Italian Protocol” with a longer stabilization phase and 
longer provocative phase. 
Stabilization phase: The tilt was performed only after an initial observation period in the supine 
posture for 20 minutes.  
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Passive phase: 20 minutes of passive tilt at 60 degree tilt 
Provocation phase: If there were no hypotension and/or bradycardia in the passive phase, 
sublingual spray of nitroglycerin 400 µg was administered at 60 degree tilt and patient was 
monitored for further 20 minutes 
The test was interrupted, and the patient was brought down to the supine position in the 
following situations:  
(1)  Completion of the schedule in the absence of symptoms (test negative).  
(2) Syncope (test positive).  
(3) Progressive, prolonged (>5 minutes) orthostatic hypotension associated with minor 
symptoms (exaggerated response) 
The test was considered positive whenever syncope (that is, the reproduction of the 
patient’s original symptoms) occurred in association with hypotension, bradycardia or both, with 
rapid (<5 minutes) onset. For the categorization of the type of response the patterns of 
hemodynamic changes until that moment (but not bradycardia occurring after the onset of 
syncope (71)) were considered. 
The patients were observed for a minimum period of 20 minutes after the test and longer 
if they continued to be symptomatic. All positive responses were classified according to the 
modified VASIS classification (21). An “exaggerated response” to nitroglycerine spray was 
interpreted as a negative response. This response was considered to be due to the 
pharmacological effects of nitrates. This response was identified by the progressive and slow (> 
5 minutes) development of decrease in systolic blood pressure with associated compensatory 
tachycardia or only minimal bradycardia.  
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Echocardiographic analysis: 
Two-dimensional echocardiography was performed using an Acuson ultrasonography 
system. An M mode image from a standard para-sternal short-axis view at the level of the LV 
papillary muscles was recorded in the supine resting stage, 1 minute after initiation of HUT, at 
5,10, 20 minutes, at 1 minute post nitrate administration, 25,30, 35 and 40 minutes and once at 
the onset of symptoms if any. LVEDD and left ventricular end-systolic dimension (LVESD) 
were determined using M-mode echocardiography. Each value obtained by averaging two 
consecutive heart beats. The corresponding blood pressure and heart rate during these 
echocardiographic recording were also recorded. FS was later calculated using the formula:  
Fractional Shortening, FS = [LVEDD-LVESD]  ×100 
                                                     LVEDD 
 
FS Change = FS at end tilt phase of HUT test- Baseline FS 
 
FS Slope = FS Change/ Time duration from start of tilt to last recording of FS at the end 
of the tilt phase  
 
 
One investigator and another health professional were present during the HUT test. 
 
Follow up:  
Follow up was done during review consults. If the patient is not able to return for a 
review consult, then telephonic interview and follow up was performed. Data regarding recurrent 
of syncope was collected during the follow up interview. Data was also collected detailing the 
medications taken and if tilt training was performed as advised. Compliance with exercise and 
drugs were also noted.  
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Sample Size Calculation: 
Assuming a syncope recurrence rate of 40% in patients with HUT positivity and 
increased FS and 10% recurrence rate in patients with HUT positivity and no increase in FS we 
needed to recruit 32 patients in each sample to demonstrate a 30% difference in proportion of 
patients with recurrent syncope between the two groups. α error was taken as 5%. Power (1-β) 
was taken as 80%. 
 
Statistical Analysis: 
Data was stored and analyzed using SPSS version 17 (SPSS Inc. Chicago, IL, USA). 
Continuous variables are expressed as mean ± SD for normally distributed variables and median 
(inter-quartile range) for not normally distributed variables. Categorical variables expressed as 
number (percentage).  Continuous variables were examined for normality of distribution using 
the Kolmogorov-Smirnov test when sample size was greater than 50 and Shapiro-Wilk test 
for less than 50. Differences in frequency of continuous variable were analyzed using 
independent sample student’s t-test for normally distributed variables. For not normally 
distributed continuous variables a non-parametric Mann Whitney test was used. For discrete 
variables, Chi square statistics (or Fisher`s exact test if applicable for a cell count less than 5) 
was used. Paired sample t-test was used for comparing the change from baseline in parameters 
monitored during HUT test at different time points. We used binary logistic regression analysis 
to identify potential predictors of positive response on HUT test and predictors of recurrence of 
syncope on follow up. All parameters which showed a p value < 0.1 during the initial analysis 
were included in the binary logistic regression analysis. A p- value of < 0.05 was considered 
statistically significant. 
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sinus in all the patients with a baseline heart rate of 79±14 beats per minute.  The median number 
of episodes of syncope prior to HUT testing was 2 (inter-quartile range 2 to 5 episodes). The 
median duration of symptoms was 12 months (inter-quartile range 6 to 24 months). The findings 
regarding clinical history are also enumerated in table 9.2. Few features atypical of reflex 
syncope were found in the cohort, including history of exertional syncope in 8.3%, convulsive 
syncope in 5%, post spell confusion in 3.3% and palpitations preceding the syncopal episode in 
15% of patients. 
 
Table 9.1 Baseline Characteristics ( Continuous Variables) 
Variable  Median (inter‐quartile range) 
Number of episodes of syncope prior to HUT test  2 (2‐5) 
Duration of symptoms (months)  12 (6‐24) 
Duration between last syncopal episode and HUT test 
(weeks) 
4.14 (1.17‐8.92) 
Table 9.2 Baseline Characteristics ( Categorical Variables) 
Variable  Number (%) n=60 
Sex (male)  38 (63.3) 
History of exertional syncope ever present: yes  5 (8.3) 
At times wake up with a cut tongue after syncope: yes  0 (0) 
Ever had a sense of aura preceding spells : yes  0 (0) 
Emotional stress ever associated with spells: yes  13 (21.7) 
Ever noted to have head turning during spells: yes  0 (0) 
Tonic posturing or jerking movements during spells: yes  3 (5) 
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Response to HUT and hemodynamic variables during HUT test  
Thirty five (58.3%) patients had positive HUT test response. Of those with a HUT positive 
response only one patient had a positive response during the drug free tilt (1.7% of the total 
population). The mean time to syncope was 31.5± 6.9 minutes. Distribution of HUT test 
responses is illustrated in Figure 4. Type 1 or mixed response was commonest (43.3%). This was 
followed by type 2A or cardio-inhibitory without asystole (8.3%). Both type 2B and type 3 
responses were rare (3.3% each). Eight patients older than 60 years had a positive HUT test 
response (72.7% of those older than 60 years). 
Figures 5 and 6 illustrate the changes in heart rate and mean arterial pressure (MAP) during 
HUT respectively. The data in figures 5-9, and in table 10, represent the measurements at five 
time-points; baseline supine state, at 5 and 10 minutes after initiation of drug free tilt, at 5 
minutes prior to end of HUT and just prior to end of HUT (if HUT test negative) or at onset of 
symptoms (if HUT test positive). The initial response to HUT was an increase in heart rate, 
which started as early as five minutes of HUT. The mean heart rate progressively increased till 
the end of tilt in HUT test negative patients. Whereas, in HUT test positive patients, heart rate 
Ever been confused after a spell: yes  2 (3.3) 
Ever had lightheaded spells: yes  38 (63.3) 
Ever sweat before spells: yes  11 (18.3) 
Prolonged standing associated with spells: yes  15 (25) 
Posture at onset of syncope: Sitting  22 (36.7) 
Posture at onset of syncope: Standing  38 (63.3) 
Palpitations preceding syncope: yes  9 (15) 
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Echocardiographic variables monitored during HUT        
The left ventricular internal dimensions during diastole and systole (LVIDD/LVIDS) 
were recorded during the supine resting stage, 1 min after initiation of HUT, at 5,10, 20 minutes, 
at 1 minute post nitrate administration, 25,30, 35 and 40 minutes and once at the onset of 
symptoms if any. The measurements at the first three and last two time points are illustrated in 
figures 7-9 and in table 10.1-10.3. The LVIDD and LVIDS decreased significantly from baseline 
in both HUT positive and negative groups during tilt. LVIDD decline started early in the HUT 
positive group. The reduction in LVIDD in HUT positive group as compared to HUT negative 
group was greater, though it was not statistically significant. There was an early onset and rapid 
decline in LVIDS in HUT positive patients as compared to HUT negative patients.  
At the end of the tilt phase, FS in the HUT positive group increased significantly from 
baseline (32.4±0.68% to 37.5±0.64 %), while FS did not change significantly in the HUT negative 
patients. This increase in FS in the HUT test positive group was apparent as early as 10 minutes 
after initiation of tilt (Figure 9). The rate of change of FS as depicted by the FS slope was 
significantly more rapid in the HUT test positive group: +0.23±0.34 %/min as compared to -
0.002±0.6 %/min in the HUT test negative groups. These changes are depicted in table 11. 
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Table 10.1. Echocardiographic and Hemodynamic Parameters at Specified Time Periods During HUT test: Time 
Trend for HUT Positive Patients  
Baseline 
supine 
Baseline+ 5 
min Baseline+10 min End - 5 min End 
HR(beats/min) 78±2 83±2 * 86±2 ‡ 109±3 ‡ 60±3 ‡ 
LVIDD mm 42.1±0.55  40.6±0.58 ‡ 40.4±0.64 ‡ 39.4±0.76 ‡ 39.0±0.74 ‡ 
LVIDS mm 28.4±0.43 27.0±0.42 ‡ 26.5±0.49 ‡ 25.5±0.56 ‡ 24.4±0.58 ‡ 
MAP mm Hg 86±2 89±3 88±2 79±2 ‡ 51±1 ‡ 
FS % 32.4±0.68 33.5±0.56 * 34.4±0.57 ‡ 35.1±0.65 ‡ 37.5±0.64 ‡ 
*P value <0.01, ‡ P value < 0.001 on paired samples t test compared to baseline. The time points showed in this 
table: Supine baseline, 5 minutes after start of 60 ° HUT (Baseline+5min), 10 minutes after HUT (Baseline + 
10min), 5 minutes prior to end of HUT (End- 5 min) and at onset of symptoms or just prior to end of HUT (End). 
HR: Heart rate. MAP: Mean arterial pressure. FS: Fractional Shortening.  
Table 10.2. Echocardiographic and Hemodynamic Parameters at Specified Time Periods During HUT test: Time 
Trend : HUT Negative Patients
Baseline 
supine 
Baseline+ 5 
min Baseline+10 min End - 5 min End 
HR(beats/min) 81±3 85±3 * 85±3 * 102±4 ‡ 102±4 ‡ 
LVIDD mm 41.6±0.87 41.8±0.87 41.3±0.82 39.8±0.91 ‡ 39.8±0.95 ‡ 
LVIDS mm 28.0±0.69 28.1±0.74 28.0±0.69 26.9±0.75 * 26.8±0.72 ‡ 
MAP mm Hg 88±2 88±2 88±2 82±2 ‡ 82±2 * 
FS % 32.6±0.88 32.7±0.95 32.1±0.92 32.4±0.87 32.5±0.79 
*P value <0.01, ‡ P value < 0.001 on paired samples t test compared to baseline value in each group. The time 
points showed in this table: Supine baseline, 5 minutes after start of 60 ° HUT (Baseline+5min), 10 minutes after 
HUT (Baseline + 10min), 5 minutes prior to end of HUT (End- 5 min) and at onset of symptoms or just prior to end 
of HUT (End). HR: Heart rate. MAP: Mean arterial pressure. FS: Fractional Shortening.  
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Table 10.3. Echocardiographic and Hemodynamic Parameters at Specified time Periods during HUT test: 
Time Trend: Comparison HUT+ and HUT- groups
Baseline 
supine 
Baseline+ 5 
min Baseline+10 min End - 5 min End 
HR( beats/min) 
HUT+ 78±2 83±2  86±2  109±3  60±3 ‡ 
HUT - 81±3 85±3  85±3  102±4  102±4 ‡ 
LVIDD mm 
HUT + 42.1±0.55  40.6±0.58  40.4±0.64  39.4±0.76  39.0±0.74  
HUT - 41.6±0.87 41.8±0.87 41.3±0.82 39.8±0.91  39.8±0.95  
LVIDS mm 
HUT + 28.4±0.43 27.0±0.42  26.5±0.49  25.5±0.56  24.4±0.58 * 
HUT - 28.0±0.69 28.1±0.74 28.0±0.69 26.9±0.75  26.8±0.72 * 
MAP mm Hg 
HUT + 86±2 89±3 88±2 79±2  51±1 ‡ 
HUT - 88±2 88±2 88±2 82±2  82±2 ‡ 
FS % 
HUT + 32.4±0.68 33.5±0.56  34.4±0.57  35.1±0.65 * 37.5±0.64 ‡ 
HUT - 32.6±0.88 32.7±0.95 32.1±0.92 32.4±0.87 * 32.5±0.79 ‡ 
*P value <0.01, ‡ P value < 0.001. The time points showed in this table: Supine baseline, 5 minutes after 
start of 60 ° HUT (Baseline+5min), 10 minutes after HUT (Baseline + 10min), 5 minutes prior to end of 
HUT (End- 5 min) and at onset of symptoms or just prior to end of HUT (End). HR: Heart rate. MAP: Mean 
arterial pressure. FS: Fractional Shortening. HUT+: HUT Positive. HUT-: HUT negative. 
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Table 10.4.  Echocardiographic and hemodynamic variables classified according to response 
to HUT test 
 
Variable 
HUT result 
Number (%) 
 
P value 
 Positive 
Mean ± SD 
Negative 
Mean±SD 
 
Heart rate (baseline) bpm 78±13 81±16 0.497 
Heart rate (peak) bpm 110±19 105±18 0.350 
Heart rate (minimum) bpm 59±14 80±14 0.0001 
Difference between 
maximum and minimum 
heart rate during HUT 
bpm 
52±21 25±12 0.0001 
FS (baseline) % 32.4±4.0 32.6±4.4 0.885 
FS (onset of 
symptoms/end of tilt) % 
37.5±3.8 32.5±3.9 0.0001 
FS change(absolute value) 
% 
5.0±2.9 - 0.08±2.5 0.001 
FS slope %/min 0.23±0.34 -0.002±0.6 0.001 
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Predictors of positive response to HUT 
We assessed if the baseline patient characteristics or hemodynamic/ echocardiographic 
variables measured during HUT test would predict positive response to head up tilting in this 
cohort of patients. Both HUT positive and negative groups seemed to have a similar syncopal 
burden in terms of number of syncopal episodes prior to HUT and duration of symptoms prior to 
HUT. Clinical historical features typical of reflex syncope were also similarly distributed 
between the two groups. The baseline hemodynamic parameters were also similar. In conclusion 
none of the baseline clinical variables or hemodynamic parameters was predictive of a positive 
response to HUT testing (tables 11.1 and 11.2).  
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 Table 11.1. Predictors of response to Head Up Tilt Testing: Categorical Variables 
 
 
Variable 
HUT result 
Number (%) 
 
 
p-value 
 
Odds ratio 
(95% CI) Positive 
35(58.3) 
Negative 
25(41.7) 
Sex (male) 22(62.9) 16(64) 0.928 0.95(0.32-2.76) 
Age more than 60 
years 
8 (22.0) 3 (12.0) 0.284 1.64 (0.59-4.53) 
More than 5 
syncopal episodes 
prior to HUT test 
12 (34.3) 6(24) 0.39 1.65 (0.52-5.23) 
History of 
exertional syncope 
2 (5.7) 3 (12) 0.64 0.44 (0.69-2.88) 
Emotional stress 
associated with 
spells 
8 (22.9) 5 (20) 0.79 1.18 (0.33-4.17) 
History of 
lightheaded spells 
present 
24 (68.6) 14 (56) 0.31 1.71 (0.59-4.97) 
Sweating 
preceding spells 
6 (17.1) 5 (20) 1.00 0.82 (0.22-3.08) 
Prolonged sitting/ 
standing 
associated with 
spells 
10 (28.6) 5 (20) 0.45 1.60 (0.47-5.44) 
Palpitations 
preceding spells  
6 (17.1) 3 (12) 0.72 1.51 (0.34-6.75) 
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Table 11.2. Predictors of Response to Head Up Tilt: Continuous Variables
 
 
Variable 
HUT result 
Number (%) 
 
 
P value Positive 
Mean ± SD 
Negative 
Mean ± SD 
Age (years) 46.00±16.32 46.1±13.89 0.98 
Heart rate (baseline) 
bpm 
78±13 81±16 0.497 
MAP (baseline) mm Hg 87±12 88±12 0.646 
FS (baseline) % 32.4±4.0 32.6±4.4 0.885 
 Median (IQR) Median (IQR)  
Number of prior 
syncopal episodes 
2 (2-7) 3 (2-4) 0.795 
Duration of symptoms 
(months) 
12 (6-24) 10 (4-15) 0.105 
Duration between last 
syncope and HUT test 
(weeks) 
4.25 (1.00-8.71) 3.71 (1.92-11.0) 0.799 
 
 
Follow up and predictors of recurrence of syncope  
 
We could follow up all the enrolled patients till the end of the study period. Patients were 
followed up for 6.3± 2.5 months. Ten (16.7%) patients had recurrent syncope during the follow 
up period, while 50 (83.3%) patients remained symptom free with no recurrence of syncope. 
There was no mortality reported. We evaluated the baseline clinical variables, the hemodynamic 
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and echocardiographic variables recorded during HUT test, the response to HUT test and the 
treatment received to identify potential predictors of recurrence of syncope. None of the baseline 
echocardiographic parameters, the type of HUT test response or the treatment received 
influenced the outcome. FS change during HUT test was not predictive of recurrent syncope 
(Figure 10). Those patients who had a recurrence of syncope on follow up seemed to have a non 
significant trend for shorter duration of symptoms [median (IQR) 5 (2.75-17.25) v s 12 (6-24) 
p=0.09] but similar number of syncopal episodes prior to HUT testing [median (IQR) 2 (2-10) v s 
2 (2-5), p=0.660]. Patients who had recurrence of syncope on follow up had significantly higher 
maximum heart rate during tilt (115±7 v s 106±20, p=0.018). On multivariate analysis the only 
factor that was predictive of recurrent syncope was the maximum heart rate achieved during 
HUT test. During HUT test, achieving a maximum heart rate of ≥ 108 beats per minute was 
predictive of recurrent syncope with a sensitivity of 80% and specificity of 50% based on 
receiver operating characteristic (ROC) curve analysis (Figure 11). Subgroup analysis including 
only HUT test positive patients did not identify any predictor of recurrent syncope. 
 
Table 12.1. Predictors of recurrent syncope on follow up: Categorical Variable 
 
 
Variable 
Syncope recurrence 
Number (%) 
 
p-value 
 
Odds ratio 
(95% CI) Present 
10 (16.7) 
Absent 
50 (83.3) 
Sex (male) 8 (80) 30(60) 0.299 2.66 (0.512-13.87) 
More than 5 
syncopal 
episodes prior to 
HUT test 
 
4 (40) 
 
14(28) 
 
0.468 
 
1.71 (0.41-7.00) 
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Peak HR 
achieved during 
HUT ≥ 108 
26 (52) 9 (90) 0.035 8.30 (0.97-70.55) 
HUT Positive 6 (60) 29 (58) 1.00 1.08 (0.27-4.33) 
Type 1 Positive 5 (50) 21 (42) 0.64 1.38 (0.35-5.38) 
Type 2A Positive 1 (10) 4 (8) 1.00 1.27 (0.12-12.80) 
Type 2B Positive 0 (0) 2 (4) 1.00 1.20 (1.07-1.35) 
Type 3 Positive 0 (0) 2 (4) 1.00 1.20 (1.07-1.35) 
HUT Negative 4(40) 21 (42) 1.00 0.92 (0.23-3.67) 
Use of beta-
blockers on 
follow up 
 
6(60) 
 
22(44) 
 
0.49 
 
1.90 (0.47-7.61) 
Use of 
Metoprolol on 
follow up 
3 (30) 9(18) 0.40 1.95 (0.42-9.04) 
Use of Atenolol 
on follow up 
3 (30) 8 (16) 0.37 2.25 (0.47-10.59) 
Use of Bisoprolol 
on follow up 
0 (0) 5 (10) 0.67 1.22 (1.07-1.38) 
Tilt training done  4 (40) 19 (38) 1.00 1.08 (0.27-4.35) 
 
Table 12.2. Predictors of recurrent syncope on follow up: Continuous Variables 
 
 
Variable 
Syncope Recurrence 
Mean ± SD 
 
p- value 
Present 
(N=10) 
Absent 
(N=50) 
Age (years) 45.08±13.79 46.23±15.62 0.829 
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Heart rate (baseline) bpm 84±10 78±15 0.284 
Heart rate (peak) bpm 115±7 106±20 0.018 
Heart rate (minimum) bpm 72±17 67±17 0.364 
MAP (baseline) mm Hg 90±16 87±11 0.394 
MAP (end of tilt) mm Hg 65±19 63±17 0.694 
FS (baseline) % 34.5±4.0 32.1±4.1 0.16 
FS change(absolute value) % 3.2±2.88 2.8±3.9 0.795 
Follow up duration          
( months) 
5.85±3.70 6.39±2.30 0.668 
 Median (IQR) Median (IQR)  
Number of prior syncopal 
episodes 
2 (2-10) 2 (2-5) 0.660 
Duration of symptoms 
(months) 
5 (2.75-17.25) 12 (6-24) 0.099 
FS slope %/min 0.11(0.02-0.15) 0.09 (0.01-0.19) 0.937 
 
Following parameters 
for HUT positive 
patients alone:  
N=35 
 
Syncope 
Recurrence 
 
Syncope 
Recurrence 
 
 
 
P value 
N=6 N=29 
Time of onset of 
syncope during HUT 
minutes Mean ± SD 
32.83±3.32 31.24±7.49 0.616 
FS change (absolute 
value) % Mean ± SD 
4.9±2.4 5.1±3.1 0.88 
Tilt training done on 
follow up: Number 
(%) 
3 (50) 17(58.6) 1.00 
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Two patients underwent pacemaker implantation on follow up. One HUT negative patient 
underwent VDDR pacemaker implantation for significant AV conduction disease. Another HUT 
negative patient had recurrent syncope and underwent pacemaker implantation at another 
hospital. Another patient with type 2B response underwent EP study and was found to have sinus 
node dysfunction and hence was advised pacemaker implantation.  
Therapy did not alter the recurrence of syncope. We analyzed the use of atenolol, 
metoprolol and bisoprolol separately. None of these drugs were associated with a decrease in the 
incidence of recurrent syncope. Fludrocortisone was not prescribed to any of these patients. Tilt 
training was advocated to all HUT positive patients, however only 57.1% of patients with a 
positive HUT test response were performing tilt training at the end of the follow up period. 
Despite performing tilt training with adequate compliance, it was not associated with a 
significant decline in the incidence of recurrent syncope.  
Table 13. Logistic Regression: Predictors of Recurrent Syncope Multivariate Analysis 
  
OR (95% CI) 
 
P value 
Duration of symptoms in months 0.99 (0.96-1.02) 0.702 
Peak HR achieved during HUT ≥ 108 8.62 (1.002-73.84) 0.049 
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DISCUSSION 
Baseline Characteristics: 
The mean age of the present study cohort was 46 ±15 years, with a demographic profile 
similar to a series of 640 patients reported by Kazemi, et al (99). The median duration of 
symptoms prior to HUT test was 12 months and the onset of symptoms was in the fourth decade 
of life, which appear to be older than that reported in a community survey done by Colman, et al 
(100). The majority of subjects in this community survey had experienced neurocardiogenic 
syncope as teenagers and adolescents while only 5% of patients had the first episode after the age 
of 40 years (100). This difference in the age of onset of symptoms can be explained by the recall 
bias that patients may have. Patients may not recall the initial episodes of syncope which occur 
in adolescence, thus affecting the accuracy of the estimated duration of symptoms. An alternative 
explanation is referral bias. Colman’s review was a community based study and our data was 
obtained from a tertiary referral centre with a dedicated electrophysiology unit. Only a small 
fraction of patients in the community experiencing syncope, seek medical consultation. Younger 
patients are less likely to seek medical care as compared to older patients for complaints of 
syncope (14).  The initial episode of syncope has a bimodal distribution, with a high prevalence 
of first faints in patients in second and third decades of life, with a peak of about 47% in females 
and 31% in males occurring in the second decade of life (101). The second peak occurs after the 
age of 65 for both males and females (102). However we could not demonstrate such a pattern, 
probably because we excluded patients presenting with a single episode of syncope. 
The effect of age on the results of HUT test has been studied. Kochiadakis, et al, 
demonstrated that age predicted a different type of syncopal response to HUT testing (103). The 
response is predominantly cardio-inhibitory or mixed in young patients and vasodepressor in 
elderly patients. Similarly in our cohort, all the patients with pure vasodepressor response to 
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HUT were more than 65 years of age (25% of patients older than 65). A number of explanations 
for this phenomenon have been proposed. Sympathetic withdrawal in response to tilt is more 
pronounced in older subjects (103). Also in elderly subjects, the autonomic nervous system is 
unable to make the appropriate compensatory heart rate changes in response to the orthostatic 
stress (104). In our cohort 22% of HUT positive patients were older than 60 years. It has been 
shown that NTG may have different pharmacodynamic properties in the older patients. NTG 
causes greater vasodilatation in older patients probably due to the decreased intravascular 
volume in this population (105).  
 
Echocardiography during HUT test: 
The use of HUT testing has become widespread, especially for unmasking susceptibility 
to vasovagal faint in subjects with presenting with syncope of unknown cause, despite the lack of 
an accepted diagnostic “gold standard” for reflex syncope. The high unexplained syncope rate in 
both general and specialist referral settings justify new strategies for evaluation and diagnosis of 
syncope. 
Studies have analyzed the utility of echocardiography during HUT testing for providing 
additional diagnostic information (11,19,20,79,83). Even though tilt induced syncopal response 
can occur in healthy volunteers (false positive), the hemodynamic as well as humoral changes 
that accompany this response are qualitatively distinct from those of HUT positive patients who 
complaint of syncopal spells during normal daily activities (true positive) (11). In patients with 
neurally mediated syncope it has been shown that there is more rapid peripheral blood pooling as 
shown by a more marked and rapid decline in LVIDD as compared to healthy HUT positive 
volunteers. These patients are also shown to have higher LV contractility as indicated by values 
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of FS as compared to healthy HUT positive healthy volunteers (11). This is mediated by higher 
levels of epinephrine in the first group (11).  
FM Leonelli, et al suggested that the false positive group of patients in those undergoing 
HUT testing for unexplained syncope, may be identified by using echocardiographic parameters 
like FS and LVIDD (11). An increase in FS from baseline (FS change) during HUT test may be 
used as a surrogate marker for identifying true positive patients. Similar to the findings in 
Leonelli’s study we found that in HUT positive patients, there is an early onset significant 
increase in LV FS during tilt as compared to HUT negative patients. The decrease in LVIDD 
during HUT is a marker of peripheral venous pooling. In our cohort there was a non significant 
trend for greater decrease of LVIDD in HUT positive patients as compared to HUT negative 
patients (Figure 6). To the best of our knowledge no study has earlier analyzed the utility of 
echocardiographic parameters measured during HUT for predicting clinical outcomes. 
 
Predictors of a positive HUT response: 
Our study sought to determine the predictors of a positive HUT response, including the 
clinical history, baseline hemodynamic and echocardiographic parameters recorded during HUT 
test in patients with unexplained syncope. Oh, et al, undertook a similar study in 711 patients. In 
their series vasodepressive type was the predominant pattern of positive response (76.6%), 
compared to only 3.3% in our series. They found the occurrence of junctional rhythm to be a 
predictor of an impending positive response to HUT. The shorter time interval between the last 
episode and HUT test, younger age and a history of physical injury during a syncopal episode 
were found to be associated with a positive response to HUT (106). In our cohort, which was 
much smaller, compared to the above mentioned series, we found that none of the clinical history 
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or baseline hemodynamic/echocardiographic parameters other than FS change were predictive of 
a positive response to HUT. FS change can be considered to be an early marker for identifying 
HUT positive response (Figure 9). We could demonstrate a significant increase in FS from 
baseline, with a mean increase of 5±2.9 % in patients with a positive HUT response.  
Of the 35 patients with a HUT positive response only one patient had a positive response 
during the drug free tilt (1.7% of patients undergoing HUT testing); the remaining had a positive 
response after administration of nitroglycerine. This is in contrast to data from table 5, which 
shows that studies report 10-12% passive stage positivity, for the same passive phase duration. In 
patients with unexplained syncope and a positive HUT response, the autonomic imbalance 
causing syncope begins immediately after tilt, but syncope develops much later (107). Hence   
early sympathovagal imbalance in our cohort cannot be ruled out in spite of the late occurrence 
of syncope. Our overall HUT positivity of 58.3% is slightly less than the 62-78% positivity 
reported in table 5 with a similar duration of passive tilt and a similar dose of NTG.  
 
Predictors of Recurrence of Syncope: 
Risk stratification is the cornerstone of management of syncope. The risk of sudden 
cardiac death as well as the risk of recurrence of syncope and physical injury should be assessed.  
Several risk scoring systems including the OESIL score, EGSYS score and the S. Francisco 
Syncope rule are available for predicting mortality and serious adverse effects (108)(109)(110). 
Most of the serious adverse outcomes are related to the underlying cardiac disease. We did not 
include patients with structural heart disease in our study. In addition, only 8 (13.3%) patients 
were older than 65 years, making the risk profile of our cohort low. Therefore the absence of life 
threatening events or mortality at the end of 6.3± 2.5 months of follow up was not surprising.  
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Assessment of the risk of recurrence of syncope is important; recurrent syncope 
especially without prodrome is associated with increased risk of physical injury including 
orthopedic fractures and soft tissue injury in up to 12% of patients (4).  A number of studies have 
looked at predictors of recurrent syncope in order to identify a patient subgroup with high risk of 
recurrence of syncope (1,111-113). The number of episodes of syncope during the patient’s life 
term is the strongest predictor of recurrence (111). In our study none of the baseline clinical 
variables, the echocardiographic parameters, the type of HUT test response or the treatment 
received influenced the outcome.  
We could identify only one hemodynamic variable: the maximum heart rate achieved 
during HUT test as the significant predictor of recurrent syncope. We observed that patients who 
achieved heart rate greater than 108 bpm were more likely to develop recurrence of symptoms 
(sensitivity of 80% and specificity of 50%). Tachycardia during tilt testing may be a surrogate 
marker of the sympathetic surge and epinephrine levels. Studies have shown a significantly 
higher peak epinephrine level in patients presenting with neurally mediated syncope with HUT 
positive response as compared to healthy volunteers with a HUT positive response (11). 
Epinephrine dilates skeletal muscle and splanchnic resistance vessels at concentrations measured 
in humans under stress thereby contributing to inappropriate vasodilatation (114). Epinephrine 
peaked in patients with neurocardiogenic syncope just before the occurrence of symptoms. It is 
not clear if epinephrine surge is the cause for the syncope or is just a failing compensatory 
mechanism to maintain cardiac output. Our findings suggest that the higher peak heart rate 
achieved during HUT test, may identify a subgroup of patients with increased risk of recurrence 
of syncope. In this patient subgroup further studies are required to identify the contribution of 
excess sympathetic activation to the pathogenesis of recurrent syncope. Further we need to study 
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if aggressive beta blockage in this subgroup of patients will be beneficial in preventing recurrent 
syncope. 
An increase in FS from baseline (FS change) during HUT test may be used as a surrogate 
marker for identifying true positive patients (11). True positives and false positives may have 
differences in terms of recurrence rate of syncope, the main outcome of interest in syncope 
management. Hence we generated a null hypothesis that there is no difference in FS change in 
those patients who had recurrence of syncope on follow up as compared to those who had no 
recurrence. However in our study we could not demonstrate any difference in the FS change 
during HUT test between these two groups. There was no significant difference irrespective of 
whether the whole cohort was analyzed or just the HUT test positive cohort was analyzed. 
 Sheldon, et al, demonstrated that the risk of a recurrent syncope following a positive 
response on isoproterenol challenge HUT test can be estimated from two simple clinical 
variables—the number of episodes of syncope prior to testing and the duration of symptoms prior 
to testing (113). They added that this estimate can be modified further based on whether patients 
faint or just have presyncopal symptoms during the HUT test and based on the minimum heart 
rate recorded during symptoms. There may have been a recall bias in our group of patients as 
compared to the more literate patients that were interviewed in the above mentioned study. 
Another study demonstrated that female gender, the presence of ≥ 3 syncope events before HUT, 
and arterial baroreceptor sensitivity below median value after the start of HUT or after the 
administration of NTG were significantly and independently associated with recurrence of 
syncope (115).  However we did not find a significant association between any of these factors 
and recurrence of syncope. Multiple studies have shown that the type of response to HUT testing 
does not predict future recurrence (112).  Our results confirm the same.  
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We also evaluated if the treatment received influenced the recurrence of syncope. Trials 
have shown that in patients with recurrent vasovagal symptoms triggered by stress caused by 
prolonged upright posture, the prescription of progressively longer periods of enforced upright 
posture (also known as ‘tilt training’) may decrease the recurrence of syncope (89). In our study 
cohort, all patients with a positive response on HUT were provided with oral and written 
instructions to perform tilt training exercises. However the only 57.1% of patients were 
compliant with the tilt training protocol at the end of the follow up period. In the compliant 
patients, we did not find any significant effect of tilt training on the recurrence rate of syncope. 
This may be due to the small size of the study.  
We also analyzed the pattern of beta blocker usage and its influence on the recurrence of 
syncope. Though widely used in the management of reflex syncope, multiple studies have failed 
to prove the efficacy of beta blockers in preventing recurrent syncope (91, 92). Our findings 
were consistent with these studies. Beta blockers including atenolol and metoprolol failed to 
prevent recurrent syncope. However these agents still continue to be widely used. 
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LIMITATIONS 
1. We recruited our patients from the outpatient department of cardiology units and the 
electrophysiology units. This may have caused a referral bias. Hence the pretest 
probability of having underlying arrhythmia as the cause of syncope is higher as 
compared to the general population. This may have affected the response to tilt testing. 
2. The sample size that we have used is not adequately powered to detect small differences 
in outcome. The study was designed to detect a 30% difference in outcome with 80% 
power.  
3. Inter-observer variability was not accounted for. In the measurement of 
echocardiographic parameters assessment of kappa statistic should have been ideal. 
4. FS is preload dependent. Use of preload independent variables like strain measurements 
of the LV long-axis function would have provided better insight into LV contractility 
changes (116). 
5. Intravenous cannulation decreases the specificity of tilt testing especially in elderly and 
children (117). Vascular cannulation may have decreased the specificity of HUT test in 
our study. 
6. Non invasive continuous finger blood pressure using digital photoplethysmography 
measurement has become the standard of care for monitoring blood pressure during tilt 
testing (118). However this was not available at our institution, thus limiting the 
generalizability of the study findings. 
7. Short follow up time is yet another limitation of our study. About one third of patients 
with syncope have a recurrence when followed up for 3 years (15). Hence longer follow 
up may have altered our results. 
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8. Many patients with positive tilt test have been instructed on specific physical maneuvers 
to abort the progression of presyncope to syncope. Hence many patients may just have 
presyncope on follow up and experience no syncopal episodes. This has not been 
accurately documented in the study. 
9. We used a 20 minute post nitrate tilt protocol as compared to the 15 minute post drug tilt 
in the Italian protocol. This may decrease the specificity of tilt testing. 
10. Smoking status significantly influences the response to HUT test during the post nitrate 
phase (119). We did not document the smoking status of our study patients. 
11. Monitoring of echocardiographic variables at regular intervals during HUT test may not 
be cost effective in terms of the additional diagnostic or prognostic information obtained. 
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CONCLUSIONS 
 
1. In patients with a positive response on HUT testing, there is an early onset of significant 
increase in LV fractional shortening during tilt as compared to those with a negative HUT 
response 
2. Change in LV fractional shortening during HUT is not predictive of recurrence of 
syncope on follow up 
3. Patients who have recurrence of syncope on follow up tend to have higher peak heart rate 
attained during HUT test. Hence peak heart rate attained during HUT test can be used to predict 
the risk of recurrence of syncope on follow up in patients with unexplained syncope. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
H.U.T TEST STUDY PROFOMA 
Name: 
Hosp no:  
Address:  
 
 
 
Mobile number            1:                                                            2: 
 
Enrollment number:  
1. Date of enrollment (dd/mm/yyyy): 
2. Date of birth(dd/mm/yyyy): 
3. Sex (1. Male 2. Female) :  
4. Number of episodes of syncope: 
5. Date of last episode (dd/mm/yyyy): 
6. Duration of symptoms in months: 
7. Duration of LOC during last episode of syncope in minutes:  
8.  History of exertional syncope 1. Yes 2. No 
9.   At times do you wake with a cut tongue after your spells?   1. Yes 2. No 
10.  At times do you have a sense of aura (deja vu or jamais vu) before your spells? 1. Yes 2.No 
 
11.  At times is emotional stress associated with losing consciousness? 1. Yes 2.No 
 
12.  Has anyone ever noted your head turning during a spell? 1. Yes 2.No 
 
13.  Has anyone ever noted that you are unresponsive or have no memory of your spells 
afterwards? 1. Yes 2.No 
(Score as yes for any positive response) 
 
14.  Has anyone ever noted that you are confused after a spell? 1. Yes 2.No 
 
15.  Have you ever had lightheaded spells?  1. Yes 2.No 
 
16. At times do you sweat before your spells? 1. Yes 2.No 
 
17. Is prolonged sitting or standing associated with your spells? 1. Yes 2.No 
 
18. Posture at onset of syncope 1. Sitting  2. Standing 3. Supine 4. Nonspecific 
 
19. Recovery 1. Gradual 2. Sudden 
 
20. Palpitations preceding the spell 1. Yes 2. No 
  
Baseline 
 
BP HR LVIDd LVIDs 
Supine  
 
   
Tilt start 
 
    
5 min 
 
    
10 min  
 
   
15 min  
 
   
20 min  
 
   
Post nitrate start  
 
   
5 min  
 
   
10 min  
 
   
15 min  
 
   
20 min  
 
   
Min HR……………. Max HR………………. 
 
21. Result:  
1. Type 1 Mixed 
2. Type 2A cardioinhibitory without asystole 
3. Type 2B cardioinhibitory with asystole 
4. Type 3 pure vasodepressor 
5. Orthostatic hypotension 
6. HUT negative 
Follow up: 
1. Follow up date (dd/mm/yyyy) 
2. Medication: Betablocker 1. YES 2. NO 
3. In Yes for above 1. Metoprolol 2. Atenolol 3. Not applicable 
4. Fludrocortisone 1. YES 2 NO 
5. Postrural training exercises done with > 80% compliance 1. YES 2. NO 
6. Reccurence of syncope 1. YES 2. NO 
7. Duration of LOC on reccurence 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Informed Consent form to participate in a research study  
 
Study Title: Predictors of Recurrence of Syncope in Patients with Unexplained Syncope Undergoing 
Head Up Tilt Testing: A Study Using Clinical, Hemodynamic and Echocardiographic Variables Study 
Number: 
Subject’s Initials: _________ Subject’s Name: ________ 
Date of Birth / Age:_______ 
Please initial box  
(Subject) 
(i) I confirm that I have read and understood the information sheet for the above study and have 
had the opportunity to ask questions. [ ] 
(ii) I understand that my participation in the study is voluntary and that I am free to withdraw at 
any time, without giving any reason, without my medical care or legal rights being affected. [ ] 
 (iii) I understand that the Sponsor of the clinical trial, others working on the Sponsor’s behalf, 
the Ethics Committee and the regulatory authorities will not need my permission to look at my 
health records both in respect of the current study and any further research that may be 
conducted in relation to it, even if I withdraw from the trial. I agree to this access. However, I 
understand that my identity will not be revealed in any information released to third parties or 
published. [ ] 
(iv) I agree not to restrict the use of any data or results that arise from this study provided such a 
use is only for scientific purpose(s) [ ] 
(v) I agree to take part in the above study. [ ] 
 
Signature (or Thumb impression) of the Subject/Legally Acceptable 
Representative:_____________ 
Date: _____/_____/______ 
Signatory’s Name: _________________________________ 
 
Signature of the Investigator: ________________________ 
Date: _____/_____/______ 
Study Investigator’s Name: Dr Anoop Mathew, MD 
 Signature of the Witness: ___________________________ 
Date:_____/_____/_______ 
Name of the Witness: ______________________________ 
 
 
 
 
Patient Information Sheet 
 
You are enrolled in a research study to evaluate the additional use of echocardiographic 
monitoring during HUT test.  This study will take approximately one hour.  Initially to monitor 
the blood pressure in your arteries a small catheter will be introduced into an artery in your wrist. 
You will be made to sleep on an electronically controlled tilt table and the table will be tilted up 
to an angle of 70 degrees. During this time your vital parameters will be monitored. An echo 
evaluation of your heart by keeping an ultrasound probe on your chest will be done every 5 
minutes during the test. The participation in this modification of the Head up tilt test that you are 
undergoing is purely voluntary. You have the option of undergoing the HUT test without using 
echo monitoring. You will not be penalized in any form for not participating in this study or for 
withdrawing from this study at any stage, if you desire so. In the event of any injury arising as a 
result of participation in this study treatment for the same at our institution will be provided. 
 
 
 
GLOSSARY FOR THE MASTER DATA SHEET 
Recsyncope : Recurrence of syncope on follow up 
0= No recurrence of syncope on follow up 
1= Syncope recurred on follow up 
Sex= Sex of the subject 
0= Male, 1= Female 
Syncopemorethan5: syncopal episodes prior to HUTT more than 5 
HUTpositive: Positive response on HUT test 
0= negative response on HUT testing 1= positive response on HUT testing 
Type1HUTTpositive: HUT test type 1 positive response  
0= Type 1 HUT positive 1= All else 
HUTT2Apositive: HUT test type 2A positive 
0= Type 2A HUT positive 1= All else 
HUTT2Bpositive: HUT test type 2A positive 
0= Type 2B HUT positive 1= All else 
Type3positive: HUT test type 3 positive 
0= Type 3 HUT positive 1= All else 
HUTnegative: HUT test negative response 
0= HUT negative 1= All else 
Bblockeruse: Use of beta blockers on follow up 
0 = "Patient using beta blockers on follow up" 1 = "No beta blocker use on follow up"  
Metoprololuse: Metoprolol used on follow up 
• 0 = "Metoprolol used on follow up"  
• 1 = "Metoprolol NOT used on follow up"  
Atenololuse: Atenolol used on follow up 
• 0 = "Atenolol used on follow up"  
• 1 = "Atenolol NOT use on follow up"  
Bisoprololuse: Bisoprolol used on follow up 
• 0 = "Bisoprolol used on follow up"  
• 1 = "Bisoprolol NOT used on follow up"  
Tilttrainin: Tilt training done on follow up with adequate compliance 
• 0 = "Tilt training done on follow up"  
• 1 = "Tilt training NOT done on follow up"  
Age: Age of the patinent in years 
Nosyncope: Number of episodes of syncope prior to HUT 
Duratsymptoms: Duration of symptoms in month prior to HUT 
Followmonth: duration of follow up in months 
SyncopetoHUTT: Duration between last syncopal episode and HUT 
HRbaseline: Heart rate at baseline 
HRpeak: Maximum heart rate recorded during HUT 
HRmin: Minimium HR recorded during HUT test 
MAPbaseline: Mean arterial pressure (MAP) at baseline 
MAPmin: MAP minimum recorded 
FSchange: Fractional Shortenting (FS) change during HUT test 
Syncopetime: Time in minutes at onset of syncope during HUT 
FSslope: Change in FS during HUTT %/min 
Dateenroll: Date of enrollment 
Dob: Date of birth 
Datelastsyn: Date of last episode of syncope 
Exertsyncop: History of exertrional syncope 1= Yes 2= No 
Cuttongue: Do you wake with a cut tongue after spells 1= Yes 2= No 
Dejavu: Do you  have sense of aura before the LOC 1= Yes 2= No 
Emotionstress: Is emotional stress associated with LOC 1= Yes 2= No 
Headturnin: Has anyone noted your head turning during a spell 1= Yes 2= No 
Unresponse: Ever been unresponsive, no memory of spells 1= Yes 2= No 
Confusion: Ever noted you are confused after a spell 1= Yes 2= No 
Lightheaded: Ever had lightheaded spells 1= Yes 2= No 
Sweating: Do you sweat before your spells 1= Yes 2= No 
Prolongedsitting: Is prolonged sitting or stanging associated with spells 1= Yes 2= No 
Postureonset: Posture at onset of syncope  
1= Sitting 2= Standing 3= Supine 4= Not able to specify 
Recovery: Recovery from spells 1= Gradual 2= Sudden 
Palpitations: Palpitations preceeding syncope 1= Yes 2= No 
HRTILT: Heartrate tilt start 
HR5MIN: Heartrate 5 min 
HR10MIN: Heartrate 10 min 
HR15MIN: Heartrate 15 min 
HR20MIN: Heartrate 20min 
HRNITRATE: Heartrate postnitrate start 
HR25MIN: Heartrate 25 min 
HR30MIN: Heartrate 30 min 
HR35MIN: Heartrate 35 min 
HR40MIN: Heartrate 40 min 
HREND: HR at end of HUT test 
LVIDDbase: LVIDD Baseline 
LVIDDTILT: LVIDD tilt start 
LVIDD5MIN: LVIDD 5min 
LVIDD10MIN: LVIDD 10 min 
LVIDD15MIN: LVIDD 15min 
LVIDD20MIN: LVIDD 20 min 
LVIDDNITRATE: LVIDD post nitrate 
LVIDD25MIN: LVIDD 25 min 
LVIDD30MIN: LVIDD 30 min 
LVIDD35MIN: LVIDD 35min 
LVIDD40MIN: LVIDD 40 min 
LVIDDEND: LVIDD at end of HUTT 
LVIDSbase: LVIDS Baseline 
LVIDStilt: LVIDS tilt start 
LVIDS5MIN: LVIDS 5min 
LVIDS10MIN: LVIDS 10min 
LVIDS15MIN: LVIDS 15min 
LVIDS20MIN: LVIDS 20 min 
LVIDSNITRATE: LVIDS post nitrate 
LVIDS25MIN: LVIDS 25 min 
LVIDS30MIN: LVIDS 30 min 
LVIDS35MIN: LVIDS 35min 
LVIDS40MIN: LVIDS 40 min 
LVIDSEND: LVIDS at end of HUTT 
EFENDTIME: Time of last recording of LVIDD/LVIDS 
MAPbase: MAP at baseline 
MAPtilt: MAP at tilt start 
MAP5MIN: MAP 5 minutes 
MAP10MIN: MAP 10 minutes 
MAP15MIN: MAP 15 minutes 
MAP20MIN: MAP 20 minutes 
MAPNITRATE: MAP post nitrate administration 
MAP25MIN: MAP 25 minutes 
MAP30MIN: MAP 30 minutes 
MAP35MIN: MAP 35 minutes 
MAP40MIN: MAP 40 minutes 
MAPEND: MAP at end of tilt test 
FSbaseline: Fractional Shortening at baseline 
FStilt: FS at tilt start 
FS5min: FS at 5 minutes of tilt 
FS10min: FS at 10 minutes of tilt 
FS15min: FS at 15minutes of tilt 
FS20min: FS at 20 minutes of tilt 
FSnitrate: FS post nitrate administration 
FS25min: FS at 25 minutes of tilt 
FS30min: FS at 30 minutes of tilt 
FS35min: FS at 35 minutes of tilt 
FS40min: FS at 40 minutes of tilt 
FSend: FS at just prior to syncope or at end of tilt 
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HUTT2
Aposit
ive 
HUTT2
Bposit
ive 
Type
3posi
tive 
HUT
nega
tive 
Bblo
cker
use 
Meto
prolol
use 
Aten
olol
use 
Biso
prolo
luse 
Tiltt
rain
in 
Age No
syn
cop
e 
Dur
ats
ym
pto
ms 
follo
wmo
nth 
Synco
petoH
UTT 
LAXMIDEVI 0 1 1 0 1 1 1 1 0 1 1 1 1 1 35.98 3 7 5.59 1.86 
VENKATARAM
AN G 
0 0 1 0 1 1 1 1 0 1 1 1 1 1 59.74 3 6 5.62 8.71 
KALYANI DAS 0 1 0 0 1 1 1 1 0 1 1 1 1 0 43.04 10 60 3.61 4.29 
MOHAMMED 
VR 
0 0 1 0 1 1 1 1 0 0 1 1 0 1 54.87 3 12 0.62 2.43 
BHASWARTI 
SADHUKHAN 
0 1 1 1 0 1 1 1 1 1 1 1 1 0 36.12 2 8 12.62 25.43 
MANJU BOWRI 0 1 1 1 0 1 1 1 1 0 0 1 1 0 70.36 2 12 5.59 0.14 
KAMAL 
CHAKRABORT
HY 
0 0 1 0 1 1 1 1 0 1 1 1 1 1 55.49 2 12 12.39 22.71 
SAURAV 
VERMA 
0 0 1 1 0 1 1 1 1 1 1 1 1 0 20.02 2 6 6.74 16.86 
UJJAL KUMAR 
GHOSAL 
0 0 1 1 0 1 1 1 1 0 1 1 0 0 50.62 3 60 6.90 11.86 
GOPAN NANDY 0 0 1 0 1 1 1 1 0 1 1 1 1 1 61.18 2 2 6.74 3.57 
DEBASIS PAL 0 0 0 1 1 0 1 1 1 1 1 1 1 0 32.87 10 60 6.74 12.43 
SUNIDRA 
SARKA 
0 1 0 1 0 1 1 1 1 1 1 1 1 1 40.86 7 24 7.03 2.71 
AJAYKUMAR 
KHAMRUI 
1 0 1 0 1 1 1 1 0 1 1 1 1 1 48.16 2 10 11.76 3.71 
SANDIP NATH 1 0 1 1 0 1 1 1 1 0 0 1 1 0 29.11 2 120 8.57 13.29 
SNEHASISH 
MUKHERJEE 
1 1 1 1 0 1 1 1 1 0 0 1 1 0 45.80 2 11 9.89 8.29 
GNANASEKAR 
N 
1 0 0 0 1 1 1 1 0 0 1 0 1 1 47.68 10 3 8.34 9.00 
MOHANA 
SUNDARAM 
1 0 0 1 0 1 1 1 1 1 1 1 1 0 52.86 5 36 3.48 4.43 
N MANAVALAN 1 0 0 1 0 1 1 1 1 0 0 1 1 1 71.17 10 1 1.77 0.29 
SK MOBARAK 1 0 1 0 1 1 1 1 0 0 1 0 1 1 32.03 3 6 4.53 4.43 
ASHOK 
PRASAD 
TARUN 
1 0 1 1 1 0 1 1 1 1 1 1 1 1 43.03 2 2 2.60 4.43 
LYDIA 1 1 0 1 0 1 1 1 1 1 1 1 1 1 24.94 20 4 0.99 10.00 
JITENDRA 
TALUKDAR 
1 0 1 0 1 1 1 1 0 0 1 0 1 0 56.03 2 4 6.64 13.00 
name H
R
ba
se
lin
e 
HR
pea
k 
H
R
mi
n 
M
A
Pb
as
eli
ne 
MA
Pm
in 
FSch
ange 
Sy
nc
op
eti
m
e 
FS
slo
pe 
dateenroll dob datelastsy
n 
Ex
ert
sy
nc
op 
C
utt
on
gu
e 
Dej
avu
Emo
tion
stre
ss 
H
ea
dt
ur
ni
n 
Unr
esp
ons
e 
C
on
fu
si
on 
Lig
hth
ead
ed 
MOHAMMED 
TOHID 
84 96 84 95 95 -4.99  -
0.12 
06-May-2010 06-Jan-1962 22-Apr-2010 2 2 2 2 2 2 2 1 
SANTIRAM 
BANERJEE 
76 98 82 86 53 4.39 35 0.13 12-Feb-2010 03-Feb-1942 13-Jan-2010 2 2 2 2 2 2 2 1 
SHYAM PRASAD 
SINGH 
84 112 45 97 43 10.69 31 0.34 28-Jun-2010 23-Jan-1960 02-Jun-2010 2 2 2 1 2 2 2 1 
SRIHARI DAS 50 80 45 70 40 1.88 39 0.05 12-Aug-2010 17-Jul-1964 15-Jul-2010 2 2 2 2 2 2 2 1 
RAJAVELU P 80 111 54 76 43 5.54 33 0.17 23-Aug-2010 03-Apr-1959 30-Jul-2010 2 2 2 2 2 1 2 2 
KSHUDIRAN 
JANA 
54 59 58 62 62 -0.53  -
0.01 
01-Aug-2010 01-Jul-1969 01-Jul-2010 2 2 2 2 2 2 2 2 
BALAIKUMAR 
SAHA 
72 102 53 89 45 3.55 25 0.18 28-Aug-2010 01-Sep-1957 20-Aug-2010 2 2 2 2 2 2 2 2 
PRADIP SARKAR 64 105 52 82 49 0.05 39 0.00 29-May-2010 15-Apr-1974 20-May-2010 1 2 2 2 2 2 2 1 
KIRAN DEVI 82 96 75 91 40 8.40 38 0.22 10-Jun-2010 06-Jun-1987 25-May-2010 2 2 2 1 2 2 2 1 
NITAI CHANDRA 
MAJI 
71 92 70 85 73 -2.27  -
0.06 
09-Jun-2010 15-Jul-1965 01-Jun-2010 1 2 2 2 2 2 2 2 
MOSTAQUE 
AHMED 
52 70 52 10
5 
97 -3.34  -
0.08 
15-Sep-2010 12-Dec-1954 01-Sep-2010 2 2 2 2 2 2 2 1 
JAGADISH 
CHANDRA SAHA 
80 110 54 99 59 3.41 27 0.14 08-Jun-2010 01-Aug-1960 09-Dec-2009 2 2 2 2 2 2 2 2 
SHAIK 
MAHABOOB 
SAHEB 
74 108 74 97 80 1.59  0.04 01-Jun-2010 01-Jul-1957 28-May-2010 2 2 2 2 2 2 2 1 
TULSI DE 73 123 73 92 45 4.19 38 0.11 16-Jun-2010 06-Jun-1943 10-Jun-2010 2 2 2 1 2 2 2 1 
NANU TABAURI 11
6 
112 101 10
1 
91 0.65  0.02 26-May-2010 07-Jun-1955 20-May-2010 2 2 2 2 2 2 2 2 
RUMIKA BIBI 95 120 95 83 76 3.55  0.09 20-Jun-2010 26-Apr-1994 01-Feb-2010 2 2 2 1 2 2 2 1 
LATA KAHAR 76 112 82 71 64 1.12  0.03 17-Sep-2010 01-Apr-1976 12-Sep-2010 1 2 2 2 2 1 2 1 
KARUNA SAHA 81 84 64 94 57 3.47 28 0.14 26-Jul-2010 07-Apr-1956 20-Jul-2010 2 2 2 1 2 2 2 1 
SIVAPRAKASAM 
R 
86 128 86 73 67 -4.27  -
0.11 
26-May-2010 18-Feb-1991 10-May-2010 2 2 2 2 2 2 1 2 
 
 
 
 
 
 
 
 
 
 
name H
R
ba
se
lin
e 
HR
pe
ak 
H
R
mi
n 
M
A
P
ba
se
lin
e 
MA
Pm
in 
FSch
ange 
S
yn
co
pe
ti
m
e 
FS
slo
pe 
dateenroll dob datelasts
yn 
E
xe
rt
sy
nc
o
p 
C
ut
to
n
g
ue
Dej
av
u 
Em
otio
nstr
ess 
H
ea
dt
ur
ni
n 
Un
res
po
ns
e 
C
o
nf
us
io
n 
Lig
hth
ea
de
d 
NIBARAN 
CHANDRA DAS 
10
4 
112 103 81 70 -2.90  -
0.07 
28-Sep-2010 01-Jan-1950 10-Sep-2010 2 2 2 2 2 2 1 1 
AKHIL CHANDRA 
DEBNATH 
59 76 42 82 56 9.97 35 0.33 03-Oct-2010 02-Feb-1938 03-Sep-2010 2 2 2 2 2 2 2 2 
ANANDA PAUL 66 78 64 74 65 4.60  0.12 03-Jun-2010 06-Jul-1952 01-Jun-2010 2 2 2 2 2 2 2 2 
ASHUTOSH PAUL 82 112 82 98 93 1.96  0.05 04-May-2010 06-Jun-1947 04-Jan-2010 2 2 2 1 2 2 2 1 
UMASRI 
ARCHANA 
98 120 46 70 53 1.41 30 0.06 04-Jul-2010 25-Nov-1987 30-Jun-2010 2 2 2 2 2 1 2 1 
MAYA SAHA 80 92 80 99 79 -1.29  -
0.03 
09-May-2010 02-Sep-1957 14-Dec-2009 2 2 2 1 2 2 2 2 
RAMITA ROY 90 133 90 72 70 -5.02  -
0.13 
10-May-2010 02-Sep-1989 18-Dec-2009 2 2 2 2 2 2 2 1 
PABITRA KUMAR 
GHOSH 
68 105 68 79 48 14.25 32 0.57 02-Nov-2010 01-Feb-1943 01-Nov-2010 2 2 2 2 2 2 2 2 
PADMANABHAN 
N 
83 122 75 10
0 
59 5.77 27 0.23 07-Jun-2010 26-May-1969 06-Jun-2010 2 2 2 2 2 2 2 1 
EDYFAIRLAND K 86 90 46 92 54 4.18 24 0.21 05-Aug-2010 05-Sep-1985 29-Jul-2010 2 2 2 2 2 2 2 2 
ASHIS MANDAL 88 102 42 92 51 4.22 2 2.11 05-Jun-2010 10-Feb-1973 01-Feb-2010 2 2 2 2 2 2 2 1 
SWAPAN BASU 10
1 
116 60 11
2 
64 2.53 35 0.08 10-Aug-2010 19-Jan-1960 08-Aug-2010 2 2 2 2 2 2 2 2 
PAVITHRA N 76 136 70 75 54 9.64 32 0.32 22-Jun-2010 20-Jan-1993 22-Apr-2010 2 2 2 1 2 2 2 1 
BIMAN KUMAR 
BANERJEE 
65 78 60 71 54 1.41 40 0.04 08-Aug-2010 25-Jun-1945 08-Jul-2010 2 2 2 2 2 2 2 2 
SUBRAMANIAM 
NAIDU L 
91 106 46 10
0 
64 2.74 24 0.13 08-Oct-2010 07-Jun-1961 04-Sep-2010 2 2 2 2 2 2 2 1 
MAMTA SHARMA 96 118 96 95 93 0.92  0.02 10-Sep-2010 06-Apr-1983 12-Aug-2010 2 2 2 2 2 2 2 1 
SARBANI 
BANDYAPADHYD
AY 
84 103 47 82 52 5.90 28 0.24 01-Oct-2010 05-Jun-1966 01-Sep-2010 1 2 2 2 2 2 2 1 
PUNITHA KASI 81 140 60 64 61 4.69 37 0.13 11-Oct-2010 03-Apr-1986 02-Sep-2010 2 2 2 2 2 2 2 1 
MUTHURAMU P 48 62  74 56 6.35 34 0.21 02-May-2010 02-Dec-1945 03-Apr-2010 2 2 2 2 2 2 2 1 
 
 
 
 
name H
R
ba
se
lin
e 
HR
pe
ak 
H
R
mi
n 
M
A
P
ba
se
lin
e 
MA
Pm
in 
FSch
ange 
S
yn
co
pe
ti
m
e 
FS
slo
pe 
dateenroll dob datelasts
yn 
E
xe
rt
sy
nc
o
p 
C
ut
to
n
g
ue
Dej
av
u 
Em
otio
nstr
ess 
H
ea
dt
ur
ni
n 
Un
res
po
ns
e 
C
o
nf
us
io
n 
Lig
hth
ea
de
d 
LAXMIDEVI 90 109 90 96 83 2.70  0.07 02-Aug-2010 20-Jan-1975 20-Jul-2010 1 2 2 2 2 2 2 2 
VENKATARAMAN 
G 
61 100 61 94 86 1.44  0.04 02-Aug-2010 17-Apr-1951 02-Jun-2010 2 2 2 2 2 2 2 1 
KALYANI DAS 94 137 93 84 77 2.73  0.07 01-Oct-2010 01-Jan-1968 01-Sep-2010 2 2 2 1 2 2 2 2 
MOHAMMED VR 70 90 70 80 80 -1.14  -
0.03 
01-Jan-2011 02-Mar-1956 15-Dec-2010 2 2 2 2 2 2 2 1 
BHASWARTI 
SADHUKHAN 
72 124 60 81 35 2.69 28 0.11 01-Jan-2010 01-Dec-1974 07-Jul-2009 2 2 2 2 2 2 2 1 
MANJU BOWRI 72 120 58 84 40 5.58 38 0.16 03-Aug-2010 05-Sep-1940 02-Aug-2010 2 2 2 1 2 2 2 1 
KAMAL 
CHAKRABORTHY 
56 94 56 86 71 0.05  0.00 07-Jan-2010 18-Jul-1955 01-Aug-2009 2 2 2 1 2 2 2 1 
SAURAV VERMA 92 129 63 93 52 6.05 28 0.24 29-Jun-2010 06-Jan-1991 03-Mar-2010 2 2 2 1 2 2 2 1 
UJJAL KUMAR 
GHOSAL 
71 138 64 10
1 
43 6.69 38 0.19 24-Jun-2010 02-Jun-1960 02-Apr-2010 2 2 2 2 2 2 2 1 
GOPAN NANDY 10
0 
112 95 93 86 -0.33  -
0.01 
29-Jun-2010 07-Nov-1949 04-Jun-2010 2 2 2 2 2 2 2 1 
DEBASIS PAL 60 145 40 87 56 3.23 34 0.11 29-Jun-2010 02-Mar-1978 03-Apr-2010 2 2 2 2 2 2 2 2 
SUNIDRA SARKA 85 93 60 93 49 5.60 27 0.22 21-Jun-2010 06-Mar-1970 02-Jun-2010 2 2 2 2 2 2 2 1 
AJAYKUMAR 
KHAMRUI 
81 117 81 76 69 1.22  0.03 29-Jan-2010 16-Nov-1962 03-Jan-2010 2 2 2 2 2 2 2 2 
SANDIP NATH 78 121 70 75 48 3.46 33 0.12 05-May-2010 05-Dec-1981 01-Feb-2010 2 2 2 1 2 2 2 1 
SNEHASISH 
MUKHERJEE 
99 122 99 83 56 3.41 35 0.11 24-Mar-2010 26-Mar-1965 25-Jan-2010 2 2 2 2 2 2 2 1 
GNANASEKAR N 82 104 82 10
8 
96 1.06  0.03 10-May-2010 10-May-1963 08-Mar-2010 2 2 2 2 2 2 2 1 
MOHANA 
SUNDARAM 
93 114 64 12
3 
77 3.38 30 0.14 05-Oct-2010 05-Mar-1958 04-Sep-2010 2 2 2 2 2 2 2 1 
N MANAVALAN 77 110 72 83 56 9.79 32 0.33 28-Nov-2010 12-Nov-1939 26-Nov-2010 2 2 2 2 2 2 2 2 
SK MOBARAK 83 110 83 92 87 0.56  0.01 04-Sep-2010 03-Jan-1979 04-Aug-2010 2 2 2 2 2 2 2 2 
ASHOK PRASAD 
TARUN 
70 122 32 87 45 4.50 38 0.13 02-Nov-2010 02-Jan-1968 02-Oct-2010 2 2 2 2 2 2 2 2 
LYDIA 98 120 70 73 38 4.94 29 0.20 20-Dec-2010 04-Feb-1986 11-Oct-2010 2 2 2 2 2 2 2 1 
JITENDRA 
TALUKDAR 
76 108 76 10
3 
78 -0.12  0.00 02-Jul-2010 01-Jan-1955 02-Apr-2010 2 2 2 2 2 2 2 2 
 
  
 
 
 
 
 
name S
w
ea
ti
n
g 
Pro
lon
ge
dsi
ttin
g 
Po
st
ur
eo
ns
et 
R
ec
ov
er
y 
Pal
pit
ati
on
s 
HRTI
LT 
H
R
5
MI
N 
HR
10
MI
N 
HR15
MIN 
HR2
0MIN 
HRNITR
ATE 
HR25
MIN 
HR30
MIN 
HR3
5MI
N 
H
R
40
MI
N 
HR
EN
D 
LVI
DDb
ase 
LVID
DTIL
T 
LVI
DD5
MIN 
MOHAMMED 
TOHID 
2 2 1 2 2 80 90 92 91 87 88 86 90 94 96 96 43.20 43.20 44.20 
SANTIRAM 
BANERJEE 
2 2 1 2 2 82 84 80 82 82 83 90 96 98  98 44.10 35.50 34.10 
SHYAM PRASAD 
SINGH 
1 1 1 2 2 76 76 81 78 83 82 93 112   45 34.10 32.10 31.10 
SRIHARI DAS 2 2 1 2 2 57 61 61 62 63 63 62 71 80  45 44.60 41.40 41.40 
RAJAVELU P 2 2 2 2 1 80 82 78 83 87 82 108 111   54 35.90 35.90 35.80 
KSHUDIRAN 
JANA 
2 2 1 2 1 53 51 52 52 51 52 52 54 59 58 58 43.30 43.30 43.30 
BALAIKUMAR 
SAHA 
2 1 2 1 2 74 74 75 77 78 102     53 44.10 38.20 38.20 
PRADIP SARKAR 2 2 2 2 2 63 66 72 71 75 96 105 99 95  52 41.00 39.90 39.30 
KIRAN DEVI 2 2 2 2 2 94 90 91 89 92 95 92 95 96  75 40.10 40.40 39.30 
NITAI CHANDRA 
MAJI 
2 2 2 2 2 70 72 80 75 75 83 92 89 92 87 87 44.70 46.40 44.70 
MOSTAQUE 
AHMED 
1 2 2 2 2 55 54 53 51 58 61 63 57 70 60 60 42.30 41.80 42.20 
JAGADISH 
CHANDRA SAHA 
1 1 2 2 2 84 86 85 86 90 90 110    54 46.90 46.00 45.00 
SHAIK 
MAHABOOB 
SAHEB 
2 2 2 2 2 88 83 85 88 87 86 95 104 108 11
2 
112 51.80 51.80 54.20 
TULSI DE 2 2 2 2 1 103 92 93 98 93 99 110 121 123  93 40.00 40.20 39.00 
NANU TABAURI 2 2 2 2 2 110 10
8 
104 101 109 101 108 104 108 11
2 
112 41.20 41.20 40.10 
RUMIKA BIBI 2 1 2 2 2 89 96 97 94 97 99 107 109 120 12
0 
120 39.90 39.90 39.90 
LATA KAHAR 2 1 2 2 2 86 92 82 88 95 83 106 118 112 10
7 
107 37.10 37.20 37.80 
KARUNA SAHA 1 1 2 2 2 80 80 79 80 79 84 82    64 42.40 43.00 44.10 
SIVAPRAKASAM 
R 
1 2 1 1 2 88 10
7 
106 103 112 103 120 104 112 12
8 
128 36.70 38.50 40.10 
 
 
 
 
 
name S
w
ea
ti
n
g 
Pro
lon
ge
dsi
ttin
g 
Po
st
ur
eo
ns
et 
R
ec
ov
er
y 
Pal
pit
ati
on
s 
HRTI
LT 
H
R
5
MI
N 
HR
10
MI
N 
HR15
MIN 
HR20
MIN 
HRNI
TRA
TE 
HR25
MIN 
HR3
0MIN 
HR
35
MI
N 
HR
40
MI
N 
HR
EN
D 
LVID
Dbas
e 
LVID
DTILT 
LVID
D5MI
N 
NIBARAN 
CHANDRA DAS 
1 2 1 2 2 103 10
5 
106 108 105 103 102 106 108 112 112 32.00 32.10 33.90 
AKHIL CHANDRA 
DEBNATH 
1 2 1 2 1 58 63 64 62 67 66 67 76   42 37.10 37.10 35.00 
ANANDA PAUL 1 1 2 2 1 64 67 64 66 64 64 62 64 67 78 78 40.70 38.90 37.20 
ASHUTOSH PAUL 2 2 1 2 1 82 84 84 92 91 96 120 120 112 111 111 38.40 38.60 37.80 
UMASRI 
ARCHANA 
2 1 2 1 2 94 10
1 
102 108 105 111 120    46 38.40 39.50 38.90 
MAYA SAHA 2 2 2 1 2 83 88 85 81 86 82 88 92 91 85 85 46.40 46.40 47.00 
RAMITA ROY 2 2 1 2 2 97 97 107 99 109 96 114 133 126 122 122 43.00 42.40 43.00 
PABITRA KUMAR 
GHOSH 
1 2 2 2 1 70 77 78 82 86 84 105    82 45.80 43.60 43.60 
PADMANABHAN 
N 
2 2 1 2 2 80 73 86 76 75 91 122    80 43.00 43.50 42.40 
EDYFAIRLAND K 2 2 2 2 2 87 86 90 85 90 83     46 39.50 40.70 39.50 
ASHIS MANDAL 2 1 1 2 1 102          42 45.80 45.10  
SWAPAN BASU 2 2 1 1 2 94 94 95 95 95 95 100 116   60 45.70 45.70 43.20 
PAVITHRA N 2 2 2 2 2 85 84 97 95 99 99 128 136   70 38.10 39.80 38.10 
BIMAN KUMAR 
BANERJEE 
2 2 2 2 2 64 66 62 64 66 65 73 76 78 60 60 48.30 47.40 46.60 
SUBRAMANIAM 
NAIDU L 
2 2 1 2 2 99 98 103 102 106 105     46 41.50 40.60 40.60 
MAMTA SHARMA 2 2 2 2 2 101 10
4 
114 117 112 112 112 112 118 112 112 46.60 46.60 44.90 
SARBANI 
BANDYAPADHYD
AY 
2 1 2 2 2 90 90 95 89 90 95 103    47 41.50 41.50 40.60 
PUNITHA KASI 2 1 2 2 2 96 96 100 98 98 109 105 134 140  60 39.80 38.10 38.10 
MUTHURAMU P 2 2 2 2 2 52 41 53 52 60 56 62 62   36 41.50 42.30 43.20 
 
 
 
 
 
 
name S
w
ea
ti
n
g 
Pro
lon
ge
dsi
ttin
g 
Po
st
ur
eo
ns
et 
R
ec
ov
er
y 
Pal
pit
ati
on
s 
HRTI
LT 
H
R
5
MI
N 
HR
10
MI
N 
HR1
5MI
N 
HR2
0MI
N 
HRNIT
RATE 
HR2
5MIN 
HR3
0MIN 
HR35
MIN 
HR4
0MI
N 
HRE
ND 
LVI
DDb
ase 
LVI
DDT
ILT 
LVID
D5MI
N 
LAXMIDEVI 1 2 2 2 2 92 93 93 96 96 94 106 100 102 109 109 33.90 32.20 33.90 
VENKATARAMAN 
G 
2 2 1 2 2 61 64 62 67 65 61 76 65 81 100 100 39.00 39.80 40.60 
KALYANI DAS 2 2 1 2 2 93 10
1 
102 109 104 110 122 135 137 130 130 45.70 45.70 44.90 
MOHAMMED VR 2 2 2 1 2 74 74 72 76 80 79 88 86 90 88 88 45.70 45.70 44.90 
BHASWARTI 
SADHUKHAN 
2 2 1 2 2 76 75 75 81 85 82 124    60 42.30 42.80 42.60 
MANJU BOWRI 2 2 1 2 2 80 83 84 80 86 90 100 120 118  58 42.30 42.30 41.50 
KAMAL 
CHAKRABORTHY 
2 2 1 2 2 66 71 66 68 71 82 88 94 93 89 89 39.10 39.10 38.60 
SAURAV VERMA 1 2 2 2 1 94 11
0 
105 107 107 102 129    63 45.60 44.00 44.20 
UJJAL KUMAR 
GHOSAL 
2 1 2 2 2 98 10
9 
105 105 106 106 125 120 138  64 42.20 42.30 42.00 
GOPAN NANDY 2 2 1 2 2 98 97 95 96 97 102 102 115 112 112 112 42.00 42.20 42.20 
DEBASIS PAL 2 2 2 2 2 80 80 85 78 78 90 120 145   40 44.30 43.20 43.40 
SUNIDRA SARKA 2 2 2 2 2 93 84 81 80 86 85 86    60 43.60 42.20 42.20 
AJAYKUMAR 
KHAMRUI 
2 1 2 2 2 85 84 84 86 85 109 117 105 98 96 96 45.80 45.80 46.40 
SANDIP NATH 2 1 2 2 2 82 81 92 90 92 96 110 121   70 45.70 43.70 43.40 
SNEHASISH 
MUKHERJEE 
2 2 1 2 2 85 10
6 
105 108 106 118 115 122 104  104 40.60 41.50 39.80 
GNANASEKAR N 2 1 1 2 2 95 94 95 100 98 98 102 104 103 102 102 40.60 41.50 41.00 
MOHANA 
SUNDARAM 
2 2 2 2 2 95 92 102 101 95 95 114    64 44.90 43.90 42.70 
N MANAVALAN 2 2 2 2 2 84 85 86 91 93 98 100 110   72 45.70 46.60 45.70 
SK MOBARAK 2 2 2 2 2 90 79 84 86 82 83 88 96 104 110 110 39.00 39.00 39.80 
ASHOK PRASAD 
TARUN 
2 2 2 2 2 91 87 94 97 95 96 111 122 121  32 41.50 38.10 39.00 
LYDIA 2 2 2 2 2 101 98 104 100 96 100 120    70 38.70 38.70 38.70 
JITENDRA 
TALUKDAR 
2 2 2 2 2 90 76 80 77 79 96 106 110 108 107 107 44.00 43.80 44.10 
 
 
 
 
 
name LV
ID
D1
0M
IN 
LVI
DD1
5MI
N 
LVI
DD
20
MI
N 
LVI
DD
NI
TR
AT
E 
LVI
DD2
5MI
N 
LVIDD
30MIN 
LVID
D35M
IN 
LVI
DD4
0MI
N 
LVID
DEN
D 
LVIDS
base 
LVIDStilt LVIDS5
MIN 
LVIDS1
0MIN 
LVID
S15
MIN 
LV
ID
S2
0M
IN 
LVI
DS
NIT
RA
TE 
LVID
S25
MIN 
LVIDS
30MIN 
LVID
S35
MIN 
MOHAMMED 
TOHID 
42.
80 
41.1
0 
41.
10 
41.
10 
41.1
0 
40.03 41.10 40.0
3 
40.03 28.60 28.60 30.70 28.30 28.40 27.
60 
28.4
0 
26.80 26.10 26.80 
SANTIRAM 
BANERJEE 
33.
30 
32.8
0 
33.
40 
33.
40 
32.2
0 
31.50 32.80  32.80 29.90 23.80 23.10 22.50 21.60 21.
80 
21.8
0 
22.10 21.50 20.80 
SHYAM PRASAD 
SINGH 
31.
20 
31.3
0 
31.
20 
29.
80 
27.2
0 
27.90   27.90 24.30 21.60 20.60 20.80 20.80 19.
60 
17.6
0 
17.30 16.90  
SRIHARI DAS 40.
10 
39.4
0 
38.
10 
38.
10 
37.5
0 
37.50 36.80  35.60 28.40 27.10 26.50 25.20 23.90 23.
30 
23.3
0 
23.30 24.60 23.90 
RAJAVELU P 34.
70 
35.4
0 
35.
00 
35.
10 
34.9
0 
33.10   33.10 26.50 26.40 26.30 25.10 25.20 25.
00 
25.3
0 
24.90 23.80  
KSHUDIRAN 
JANA 
43.
30 
42.0
0 
43.
30 
43.
60 
42.7
0 
42.70 40.70 41.4
0 
41.40 25.50 25.50 25.20 25.90 23.90 25.
50 
25.8
0 
26.50 25.90 24.60 
BALAIKUMAR 
SAHA 
37.
90 
37.9
0 
37.
80 
36.
40 
    36.40 30.40 26.10 26.10 26.40 26.00 26.
30 
23.8
0 
   
PRADIP SARKAR 39.
80 
39.8
0 
38.
90 
40.
30 
37.8
0 
37.80 37.90  37.90 24.90 24.90 24.70 24.50 24.60 23.
80 
24.1
0 
24.30 23.00 23.00 
KIRAN DEVI 39.
30 
36.7
0 
36.
80 
33.
70 
34.0
0 
33.70 34.80  34.90 30.60 29.10 27.60 26.70 26.60 25.
50 
24.0
0 
24.40 23.90 24.70 
NITAI CHANDRA 
MAJI 
43.
00 
43.0
0 
43.
50 
43.
50 
42.4
0 
43.00 40.10 42.4
0 
42.40 30.40 32.60 31.50 30.90 30.40 29.
80 
29.8
0 
29.80 29.20 28.10 
MOSTAQUE 
AHMED 
42.
90 
42.1
0 
42.
40 
41.
60 
41.6
0 
40.60 40.20 39.7
0 
39.70 28.10 27.40 28.10 28.10 28.80 28.
90 
28.1
0 
27.20 26.90 26.80 
JAGADISH 
CHANDRA SAHA 
46.
70 
46.0
0 
44.
20 
50.
40 
50.4
0 
   50.40 35.10 36.30 32.00 32.50 32.00 32.
50 
36.0
0 
36.00   
SHAIK 
MAHABOOB 
SAHEB 
51.
80 
51.9
0 
50.
20 
49.
30 
49.8
0 
51.70 50.60 51.0
0 
51.00 38.10 38.10 40.80 40.30 40.60 39.
30 
37.6
0 
37.60 38.20 39.50 
TULSI DE 39.
40 
39.5
0 
39.
50 
38.
30 
37.6
0 
36.90 36.50  36.30 27.90 27.80 26.90 24.80 26.60 26.
60 
25.0
0 
24.90 24.80 24.00 
NANU TABAURI 40.
70 
41.2
0 
40.
10 
41.
20 
40.1
0 
39.50 40.70 40.7
0 
40.70 27.50 28.10 26.90 26.90 27.50 27.
50 
27.5
0 
26.30 25.80 27.50 
RUMIKA BIBI 39.
20 
38.3
0 
37.
60 
36.
30 
37.3
0 
35.00 35.60 33.9
0 
33.90 29.90 29.90 29.80 28.80 28.20 26.
80 
25.3
0 
25.30 25.00 24.90 
LATA KAHAR 37.
80 
38.4
0 
37.
20 
36.
10 
35.6
0 
35.30 34.60 35.5
0 
35.50 25.60 26.30 26.90 27.50 28.10 26.
30 
25.8
0 
25.00 24.60 23.30 
KARUNA SAHA 44.
00 
43.0
0 
43.
00 
42.
40 
37.2
0 
   37.20 28.60 29.20 29.20 30.40 30.40 30.
60 
29.8
0 
23.80   
SIVAPRAKASAM 
R 
38.
20 
38.9
0 
36.
70 
35.
70 
36.2
0 
35.20 36.10 34.7
0 
34.70 23.50 25.50 24.80 25.10 25.20 23.
50 
24.1
0 
25.20 24.80 25.20 
 
name LV
ID
D1
0
MI
N 
LVI
DD
15
MIN 
LVI
DD
20
MI
N 
LVID
DNIT
RAT
E 
LVID
D25M
IN 
LVI
DD3
0MI
N 
LV
ID
D3
5
MI
N 
LVI
DD
40
MI
N 
LVIDD
END 
LVIDS
base 
LVID
Stilt 
LVIDS
5MIN 
LVID
S10M
IN 
LVI
DS
15
MI
N 
LVI
DS
20
MI
N 
LVI
DS
NIT
RA
TE 
LVID
S25M
IN 
LVIDS
30MIN 
LVIDS
35MIN 
NIBARAN 
CHANDRA DAS 
32.
50 
32.8
0 
32.
40 
31.00 30.60 29.2
0 
28.
60 
29.
20 
29.20 21.10 20.80 21.60 21.60 22.8
0 
22.8
0 
22.3
0 
21.20 20.90 20.10 
AKHIL CHANDRA 
DEBNATH 
32.
20 
32.2
0 
32.
40 
33.10 33.20 32.8
0 
  32.80 27.00 27.00 25.30 20.60 21.3
0 
21.6
0 
21.6
0 
21.60 20.60  
ANANDA PAUL 37.
20 
37.8
0 
38.
90 
37.20 38.90 37.8
0 
37.
20 
37.
60 
37.60 29.80 26.30 26.30 25.80 26.3
0 
26.9
0 
25.2
0 
26.30 25.20 25.80 
ASHUTOSH PAUL 37.
50 
38.2
0 
37.
10 
36.90 35.60 35.7
0 
36.
00 
35.
60 
35.60 26.10 26.10 26.10 26.70 27.3
0 
26.0
0 
26.2
0 
23.80 23.80 24.70 
UMASRI 
ARCHANA 
38.
40 
39.5
0 
37.
20 
37.40 37.40    37.40 25.80 25.20 26.30 25.20 26.9
0 
25.8
0 
25.8
0 
24.60   
MAYA SAHA 45.
80 
48.1
0 
47.
00 
46.40 47.00 47.0
0 
45.
80 
46.
40 
46.40 32.60 32.60 32.10 30.90 33.2
0 
32.6
0 
33.2
0 
33.80 33.80 33.20 
RAMITA ROY 41.
80 
42.4
0 
41.
20 
41.80 41.20 41.2
0 
39.
50 
40.
70 
40.70 25.10 26.90 26.30 25.80 26.3
0 
26.9
0 
25.8
0 
25.20 26.30 25.20 
PABITRA KUMAR 
GHOSH 
43.
20 
42.6
0 
41.
80 
42.40 40.90    40.90 31.50 30.20 29.70 29.20 28.5
0 
28.1
0 
28.1
0 
22.30   
PADMANABHAN 
N 
42.
40 
41.2
0 
41.
80 
42.40 37.70    37.70 28.60 28.10 27.50 28.60 26.9
0 
26.9
0 
27.5
0 
22.90   
EDYFAIRLAND K 40.
10 
39.5
0 
38.
40 
36.70     36.70 26.30 27.50 26.30 26.90 25.2
0 
25.2
0 
22.9
0 
   
ASHIS MANDAL         45.10 32.60 30.20         
SWAPAN BASU 43.
20 
44.0
0 
44.
00 
44.00 43.20 44.9
0 
  44.90 32.20 32.20 30.50 28.80 29.6
0 
29.6
0 
30.5
0 
29.60 30.50  
PAVITHRA N 38.
10 
37.3
0 
37.
30 
36.40 36.40 36.4
0 
  36.40 26.70 26.30 26.30 25.40 24.6
0 
24.6
0 
23.7
0 
23.70 22.00  
BIMAN KUMAR 
BANERJEE 
46.
60 
47.4
0 
46.
60 
46.60 46.00 45.9
0 
46.
40 
46.
00 
46.00 30.50 30.50 29.60 31.30 30.5
0 
29.6
0 
29.6
0 
28.60 28.70 29.20 
SUBRAMANIAM 
NAIDU L 
39.
80 
40.6
0 
39.
00 
40.60     40.60 27.10 27.10 26.30 26.30 26.3
0 
25.4
0 
25.4
0 
   
MAMTA SHARMA 44.
00 
43.2
0 
44.
00 
44.00 43.20 43.2
0 
44.
00 
43.
20 
43.20 28.80 28.80 26.30 26.30 25.4
0 
26.3
0 
26.3
0 
26.30 27.10 26.30 
SARBANI 
BANDYAPADHYD
AY 
39.
80 
39.8
0 
40.
60 
40.60 39.90    39.90 27.10 26.30 24.60 23.70 24.6
0 
24.6
0 
24.6
0 
23.70   
PUNITHA KASI 40.
60 
39.8
0 
39.
00 
39.00 38.10 37.3
0 
37.
30 
 37.30 26.30 25.40 24.60 26.30 25.4
0 
25.4
0 
25.4
0 
24.60 23.60 22.90 
MUTHURAMU P 42.
30 
41.5
0 
41.
50 
40.60 40.60 41.4
0 
  41.40 28.80 28.80 28.80 28.80 26.3
0 
27.1
0 
26.3
0 
26.30 26.10  
name LVI
DD1
0MI
N 
LVI
DD1
5MI
N 
LVI
DD2
0MI
N 
LVI
DD
NIT
RAT
E 
LVI
DD2
5MI
N 
LVI
DD3
0MI
N 
LVI
DD3
5MI
N 
LVI
DD
40
MI
N 
LVID
DEN
D 
LVI
DSb
ase 
LVI
DSti
lt 
LVID
S5MI
N 
LVI
DS1
0MI
N 
LVI
DS1
5MI
N 
LVI
DS2
0MI
N 
LVID
SNIT
RAT
E 
LVI
DS2
5MI
N 
LVI
DS3
0MI
N 
LVID
S35
MIN 
LAXMIDEVI 33.90 33.00 32.20 31.30 32.20 33.00 32.20 31.3
0 
31.30 22.90 22.90 22.90 23.70 21.20 21.20 20.30 21.20 21.20 21.20 
VENKATARAMAN 
G 
40.60 41.10 40.60 41.50 40.60 40.60 40.60 39.8
0 
39.80 27.90 28.40 27.10 28.80 29.60 28.80 30.50 29.60 28.80 28.80 
KALYANI DAS 44.90 44.90 44.00 44.90 43.20 43.20 44.90 44.9
0 
44.90 27.10 26.30 26.30 26.30 25.40 25.40 25.40 23.70 23.70 25.40 
MOHAMMED VR 45.70 44.90 44.00 44.90 45.70 44.90 44.00 44.0
0 
44.00 29.60 29.60 29.60 30.50 30.50 28.80 30.50 30.50 30.50 29.00 
BHASWARTI 
SADHUKHAN 
41.50 41.50 40.90 41.50 40.60    40.60 27.60 27.60 27.40 26.30 26.30 26.30 27.10 25.40   
MANJU BOWRI 40.60 40.60 41.50 39.80 39.80 39.80 39.80  39.80 26.70 26.00 25.40 24.60 24.60 25.40 24.60 23.70 22.90 22.90 
KAMAL 
CHAKRABORTHY 
38.60 38.10 39.10 36.10 37.00 37.00 37.70 38.0
0 
38.00 27.70 27.90 28.50 28.50 27.60 27.90 25.90 26.20 26.70 26.20 
SAURAV VERMA 44.00 44.50 43.80 44.50 43.80    43.80 31.70 30.40 29.70 29.90 29.10 28.60 29.00 27.80   
UJJAL KUMAR 
GHOSAL 
42.10 40.80 41.90 41.50 41.50 41.00 41.30  41.30 29.80 29.80 29.60 29.00 28.20 28.80 27.90 29.80 27.10 26.40 
GOPAN NANDY 41.00 41.00 40.90 41.60 40.80 41.30 41.10 41.8
0 
41.80 29.00 29.00 29.10 28.60 28.50 28.80 29.00 28.20 28.40 27.90 
DEBASIS PAL 43.20 42.80 43.20 43.20 43.20 43.10   43.10 29.80 28.80 29.00 28.20 28.00 28.00 28.00 27.60 27.60  
SUNIDRA SARKA 42.00 42.40 41.80 41.80 41.80    41.80 30.50 29.40 29.00 28.60 28.70 28.00 28.00 26.90   
AJAYKUMAR 
KHAMRUI 
45.80 44.10 45.80 44.10 41.80 41.80 42.40 42.4
0 
42.40 32.10 32.10 32.10 31.50 30.90 32.60 29.80 28.10 28.60 28.60 
SANDIP NATH 42.80 43.30 44.00 42.50 43.20 41.50   41.50 27.90 28.00 27.80 26.00 26.30 26.30 25.90 25.90 23.90  
SNEHASISH 
MUKHERJEE 
40.60 39.80 41.50 41.50 40.60 39.00   39.00 24.60 25.40 24.60 23.70 24.60 25.40 24.60 23.70 22.30  
GNANASEKAR N 40.80 40.80 40.00 39.50 40.70 39.80 41.00 39.5
0 
39.50 28.80 29.60 28.90 27.70 27.70 27.10 26.80 28.60 27.70 28.90 
MOHANA 
SUNDARAM 
43.90 42.30 43.10 42.10 42.10    42.10 30.10 29.20 29.10 29.20 27.10 28.50 26.30 26.80   
N MANAVALAN 46.60 44.90 45.70 45.70 43.30 43.00   43.00 30.30 30.50 29.60 29.60 29.60 29.60 29.60 26.60 24.30  
SK MOBARAK 39.80 40.60 39.80 39.00 38.10 38.10 39.00 38.1
0 
38.10 25.40 26.30 26.30 26.30 27.90 27.10 26.30 24.60 25.40 25.40 
ASHOK PRASAD 
TARUN 
37.30 37.30 36.40 37.30 36.40 36.40 35.60  35.60 24.60 22.90 23.70 22.00 21.20 21.20 22.00 21.20 21.20 19.50 
LYDIA 37.70 37.80 37.80 36.90 36.90    36.90 25.30 25.30 24.60 24.60 23.40 23.40 23.00 22.30   
JITENDRA 
TALUKDAR 
44.00 43.70 43.50 43.20 44.00 43.00 43.20 43.2
0 
43.20 30.40 29.90 30.20 30.20 30.00 29.90 29.90 29.90 28.90 29.90 
 
 
name LVI
DS
40
MI
N 
LVI
DSE
ND 
EFE
NDT
IME 
MA
Pb
as
e 
MA
Ptilt 
MA
P5M
IN 
MAP
10MI
N 
MA
P1
5M
IN 
MA
P2
0M
IN 
MAP
NITR
ATE 
MA
P25
MIN 
MA
P30
MIN 
MAP
35MI
N 
MA
P4
0M
IN 
MA
PE
ND 
FSba
seline 
FSti
lt 
FS5
min 
FS1
0mi
n 
MOHAMMED 
TOHID 
28.5
0 
28.50 40.00 95 96 97 100 95 99 96 99 98 95 97 97 33.80 33.80 30.54 33.88 
SANTIRAM 
BANERJEE 
 20.80 35.00 86 90 85 85 86 86 90 90 60   53 32.20 32.96 32.26 32.43 
SHYAM PRASAD 
SINGH 
 16.90 31.00 97 105 97 100 95 100 99 103 67   43 28.74 32.71 33.76 33.33 
SRIHARI DAS  22.00 39.00 70 70 75 74 72 75 75 72 68 57  40 36.32 34.54 35.99 37.16 
RAJAVELU P  22.60 32.00 76 75 81 86 86 81 81 76 79   43 26.18 26.46 26.54 27.67 
KSHUDIRAN 
JANA 
24.6
0 
24.60 40.00 62 86 74 74 73 72 72 76 74 71 67 67 41.11 41.11 41.80 40.18 
BALAIKUMAR 
SAHA 
 23.80 20.00 89 92 92 92 92 93 96     45 31.07 31.68 31.68 30.34 
PRADIP SARKAR  23.00 35.00 82 104 97 82 80 82 80 78 75 59  49 39.27 37.59 37.15 38.44 
KIRAN DEVI  23.70 38.00 91 91 86 83 84 85 86 83 85 82  40 23.69 27.97 29.77 32.06 
NITAI CHANDRA 
MAJI 
29.8
0 
29.80 40.00 85 96 89 81 91 83 89 89 80 75 73 73 31.99 29.74 29.53 28.14 
MOSTAQUE 
AHMED 
27.7
0 
27.70 40.00 105 101 97 97 101 102 102 102 88 89 97 97 33.57 34.45 33.41 34.50 
JAGADISH 
CHANDRA SAHA 
 36.00 25.00 99 128 142 134 125 130 138 85    59 25.16 21.09 28.89 30.41 
SHAIK 
MAHABOOB 
SAHEB 
36.7
0 
36.70 40.00 97 101 102 102 98 98 102 95 91 83 80 80 26.45 26.45 24.72 22.20 
TULSI DE  23.80 38.00 92 90 91 87 83 75 83 84 86 83  45 30.25 30.85 31.03 37.06 
NANU TABAURI 26.9
0 
26.90 40.00 101 112 105 105 105 101 101 108 104 91 94 94 33.25 31.80 32.92 33.91 
RUMIKA BIBI 24.2
0 
24.20 40.00 83 89 91 76 78 78 79 84 81 73 88 88 25.06 25.06 25.31 26.53 
LATA KAHAR 24.1
0 
24.10 40.00 71 71 71 79 58 64 64 63 64 67 74 74 31.00 29.30 28.84 27.25 
KARUNA SAHA  23.80 25.00 94 89 84 84 86 88 85 79    57 32.55 32.09 33.79 30.91 
SIVAPRAKASAM 
R 
23.7
0 
23.70 40.00 73 72 71 75 70 74 74 73 67 67 70 70 35.97 33.77 38.15 34.29 
 
 
 
 
 
 
 
name LVI
DS4
0MI
N 
LVIDS
END 
EFE
NDTI
ME 
M
A
P
ba
se 
M
A
Pt
ilt 
MA
P5
MI
N 
M
A
P
10
MI
N 
M
AP
15
MI
N 
MAP2
0MIN 
MAPN
ITRAT
E 
MAP
25MI
N 
MA
P30
MI
N 
MA
P35
MIN 
MA
P40
MIN 
MA
PE
ND 
FSba
selin
e 
FStilt FS5m
in 
FS10
min 
NIBARAN 
CHANDRA DAS 
20.10 20.10 40.00 81 81 81 80 78 80 78 85 78 73 70 70 34.06 35.20 36.28 33.54 
AKHIL 
CHANDRA 
DEBNATH 
 20.60 30.00 82 82 84 85 85 84 82 81 83   56 27.22 27.22 27.71 36.02 
ANANDA PAUL 25.80 25.80 40.00 74 74 73 75 70 70 70 70 69 65 65 65 26.78 32.39 29.30 30.65 
ASHUTOSH 
PAUL 
23.50 23.50 40.00 98 99 99 10
0 
99 101 98 89 89 93 93 93 32.03 32.38 30.95 28.80 
UMASRI 
ARCHANA 
 24.60 25.00 70 69 69 70 68 69 68 66    53 32.81 36.20 32.39 34.38 
MAYA SAHA 33.20 33.20 40.00 99 92 93 92 94 91 93 89 87 89 79 79 29.74 29.74 31.70 32.53 
RAMITA ROY 25.80 25.80 40.00 72 73 74 75 82 86 83 79 75 69 70 70 41.63 36.56 38.84 38.28 
PABITRA 
KUMAR GHOSH 
 22.30 25.00 79 87 83 77 78 80 79 79    48 31.22 30.73 31.88 32.41 
PADMANABHA
N N 
 22.90 25.00 10
0 
10
0 
94 10
3 
106 103 107 89    59 33.49 35.40 35.14 32.55 
EDYFAIRLAND 
K 
 22.90 20.00 92 92 91 89 88 87 83     54 33.42 32.43 33.42 32.92 
ASHIS MANDAL  30.20 2.00 92 75          51 28.82 33.04   
SWAPAN BASU  30.50 30.00 11
2 
11
5 
115 11
7 
116 113 108 103 105   64 29.54 29.54 29.40 33.33 
PAVITHRA N  22.00 30.00 75 87 87 77 77 80 86 92 90   54 29.92 33.92 30.97 33.33 
BIMAN KUMAR 
BANERJEE 
28.40 28.40 40.00 71 68 67 70 68 70 70 71 62 52  54 36.85 35.65 36.48 32.83 
SUBRAMANIAM 
NAIDU L 
 25.40 21.00 10
0 
10
3 
111 11
4 
108 105 97     64 34.70 33.25 35.22 33.92 
MAMTA 
SHARMA 
26.30 26.30 40.00 95 93 91 90 85 97 92 96 96 92 95 95 38.20 38.20 41.43 40.23 
SARBANI 
BANDYAPADH
YDAY 
 23.70 25.00 82 85 74 74 78 78 72 79    52 34.70 36.63 39.41 40.45 
PUNITHA KASI  22.90 35.00 64 77 80 78 77 77 78 76 77 72  61 33.92 33.33 35.43 35.22 
MUTHURAMU P  26.10 30.00 74 77 82 81 79 82 75 68 65   56 30.60 31.91 33.33 31.91 
 
 
 
 
 
name LVI
DS4
0MI
N 
LVI
DSE
ND 
EFE
NDT
IME 
MA
Pba
se 
MA
Ptilt 
MA
P5M
IN 
MA
P10
MIN 
MA
P1
5M
IN 
MAP
20MI
N 
MA
PNI
TRA
TE 
MA
P25
MIN 
MAP
30MI
N 
MA
P35
MIN 
MA
P40
MIN 
MA
PEN
D 
FSba
selin
e 
FSti
lt 
FS5
min 
FS10
min 
LAXMIDEVI 20.30 20.30 40.00 96 91 88 87 84 86 84 83 84 83 83 83 32.45 28.88 32.45 30.09 
VENKATARAMAN 
G 
27.90 27.90 40.00 94 93 92 88 89 91 97 97 97 90 86 86 28.46 28.64 33.25 29.06 
KALYANI DAS 25.40 25.40 40.00 84 84 84 86 85 87 89 89 81 83 77 77 40.70 42.45 41.43 41.43 
MOHAMMED VR 29.00 29.00 40.00 80 83 84 83 87 88 88 75 76 71 85 85 35.23 35.23 34.08 33.26 
BHASWARTI 
SADHUKHAN 
 25.40 25.00 81 83 82 81 79 75 76 82    35 34.75 35.51 35.68 36.63 
MANJU BOWRI  22.90 35.00 84 85 91 91 86 84 91 87 89 87  40 36.88 38.53 38.80 39.41 
KAMAL 
CHAKRABORTHY 
26.90 26.90 40.00 86 85 78 86 84 90 90 76 83 84 71 71 29.16 28.64 26.17 26.17 
SAURAV VERMA  27.80 25.00 93 88 87 87 89 85 91 77    52 30.48 30.91 32.81 32.05 
UJJAL KUMAR 
GHOSAL 
 26.40 35.00 101 100 102 105 106 101 101 99 99 79  43 29.38 29.55 29.52 31.12 
GOPAN NANDY 29.00 29.00 40.00 93 94 92 90 88 86 90 93 95 97 95 95 30.95 31.28 31.04 30.24 
DEBASIS PAL  27.60 30.00 87 89 87 93 81 81 81 75 68   56 32.73 33.33 33.18 34.72 
SUNIDRA SARKA  26.90 25.00 93 80 87 92 84 91 86 86    49 30.05 30.33 31.28 31.90 
AJAYKUMAR 
KHAMRUI 
29.20 29.20 40.00 76 83 80 80 79 78 91 69 69 76 74 74 29.91 29.91 30.82 31.22 
SANDIP NATH  23.90 30.00 75 71 68 67 69 70 76 69 67   48 38.95 35.93 35.94 39.25 
SNEHASISH 
MUKHERJEE 
 22.30 30.00 83 87 97 88 89 86 95 92 89   56 39.41 38.80 38.19 41.63 
GNANASEKAR N 27.60 27.60 40.00 108 115 104 98 96 96 98 98 98 97 96 96 29.06 28.67 29.51 32.11 
MOHANA 
SUNDARAM 
 26.80 25.00 123 113 113 110 113 105 113 106    77 32.96 33.49 31.85 33.49 
N MANAVALAN  24.30 30.00 83 78 73 75 79 75 76 73 69   56 33.70 34.55 35.23 36.48 
SK MOBARAK 24.60 24.60 40.00 92 92 99 102 100 100 99 94 96 92 87 87 34.87 32.56 33.92 33.92 
ASHOK PRASAD 
TARUN 
 19.50 35.00 87 90 84 88 90 91 82 83 78 78  45 40.72 39.90 39.23 41.02 
LYDIA  22.30 25.00 73 76 84 79 81 78 81 80    38 34.63 34.63 36.43 34.75 
JITENDRA 
TALUKDAR 
29.90 29.90 40.00 103 99 97 93 95 90 87 86 82 85 78 78 30.91 31.74 31.52 31.36 
 
 
 
 
 
 
 
 
 
 
 
name FS15min FS20min FSnitrate FS25min FS30min FS35min FS40min FSend
MOHAMMED TOHID 30.90 32.85 30.90 34.79 34.80 34.79 28.80 28.80 
SANTIRAM BANERJEE 34.15 34.73 34.73 31.37 31.75 36.59  36.59 
SHYAM PRASAD 
SINGH 
33.55 37.18 40.94 36.40 39.43   39.43 
SRIHARI DAS 39.34 38.85 38.85 37.87 34.40 35.05  38.20 
RAJAVELU P 28.81 28.57 27.92 28.65 28.10   31.72 
KSHUDIRAN JANA 43.10 41.11 40.83 37.94 39.34 39.56 40.58 40.58 
BALAIKUMAR SAHA 31.40 30.42 34.62     34.62 
PRADIP SARKAR 38.19 38.82 40.20 35.71 39.15 39.31  39.31 
KIRAN DEVI 27.52 30.71 28.78 28.24 29.08 29.02  32.09 
NITAI CHANDRA MAJI 29.30 31.49 31.49 29.72 32.09 29.93 29.72 29.72 
MOSTAQUE AHMED 31.59 31.84 32.45 34.62 33.74 33.33 30.23 30.23 
JAGADISH CHANDRA 
SAHA 
30.43 26.47 28.57 28.57    28.57 
SHAIK MAHABOOB 
SAHEB 
21.77 21.71 23.73 24.50 26.11 21.94 28.04 28.04 
TULSI DE 32.66 32.66 34.73 33.78 32.79 34.25  34.44 
NANU TABAURI 33.25 31.42 33.25 34.41 34.68 32.43 33.91 33.91 
RUMIKA BIBI 26.37 28.72 30.30 32.17 28.57 30.06 28.61 28.61 
LATA KAHAR 26.82 29.30 28.53 29.78 30.31 32.66 32.11 32.11 
KARUNA SAHA 29.30 28.84 29.72 36.02    36.02 
SIVAPRAKASAM R 35.22 35.97 32.49 30.39 29.55 30.19 31.70 31.70 
NIBARAN CHANDRA 
DAS 
30.49 29.63 28.06 30.72 28.42 29.72 31.16 31.16 
AKHIL CHANDRA 
DEBNATH 
33.85 33.33 34.74 34.94 37.20   37.20 
ANANDA PAUL 30.42 30.85 32.26 32.39 33.33 30.65 31.38 31.38 
ASHUTOSH PAUL 28.53 29.92 29.00 33.15 33.33 31.39 33.99 33.99 
UMASRI ARCHANA 31.90 30.65 31.02 34.22    34.22 
MAYA SAHA 30.98 30.64 28.45 28.09 28.09 27.51 28.45 28.45 
RAMITA ROY 37.97 34.71 38.28 38.83 36.17 36.20 36.61 36.61 
PABITRA KUMAR 
GHOSH 
33.10 32.78 33.73 45.48    45.48 
PADMANABHAN N 34.71 35.65 35.14 39.26    39.26 
EDYFAIRLAND K 36.20 34.38 37.60     37.60 
ASHIS MANDAL        33.04 
 
 
 
 
 
 
 
 
name FS15min FS20min FSnitrate FS25min FS30min FS35min FS40min FSend
 
SWAPAN BASU 32.73 32.73 30.68 31.48 32.07   32.07 
PAVITHRA N 34.05 34.05 34.89 34.89 39.56   39.56 
BIMAN KUMAR 
BANERJEE 
35.65 36.48 36.48 37.83 37.47 37.07 38.26 38.26 
SUBRAMANIAM NAIDU 
L 
35.22 34.87 37.44     37.44 
MAMTA SHARMA 41.20 40.23 40.23 39.12 37.27 40.23 39.12 39.12 
SARBANI 
BANDYAPADHYDAY 
38.19 39.41 39.41 40.60    40.60 
PUNITHA KASI 36.18 34.87 34.87 35.43 36.73 38.61  38.61 
MUTHURAMU P 36.63 34.70 35.22 35.22 36.96   36.96 
LAXMIDEVI 35.76 34.16 35.14 34.16 35.76 34.16 35.14 35.14 
VENKATARAMAN G 27.98 29.06 26.51 27.09 29.06 29.06 29.90 29.90 
KALYANI DAS 43.43 42.27 43.43 45.14 45.14 43.43 43.43 43.43 
MOHAMMED VR 32.07 34.55 32.07 33.26 32.07 34.09 34.09 34.09 
BHASWARTI 
SADHUKHAN 
36.63 35.70 34.70 37.44    37.44 
MANJU BOWRI 39.41 38.80 38.19 40.45 42.46 42.46  42.46 
KAMAL 
CHAKRABORTHY 
27.56 28.64 28.25 29.19 27.84 30.50 29.21 29.21 
SAURAV VERMA 34.61 34.70 34.83 36.53    36.53 
UJJAL KUMAR 
GHOSAL 
30.88 31.26 32.77 28.19 33.90 36.08  36.08 
GOPAN NANDY 30.49 29.58 30.29 30.88 31.23 32.12 30.62 30.62 
DEBASIS PAL 34.58 35.19 35.19 36.11 35.96   35.96 
SUNIDRA SARKA 32.31 33.01 33.01 35.65    35.65 
AJAYKUMAR 
KHAMRUI 
29.93 28.82 32.43 32.78 31.58 32.55 31.13 31.13 
SANDIP NATH 39.26 40.23 39.06 40.05 42.41   42.41 
SNEHASISH 
MUKHERJEE 
38.19 38.80 40.72 41.63 42.82   42.82 
GNANASEKAR N 32.11 32.25 32.15 29.73 30.40 29.51 30.13 30.13 
MOHANA SUNDARAM 35.93 33.87 37.53 36.34    36.34 
N MANAVALAN 34.08 35.23 35.23 38.57 43.49   43.49 
SK MOBARAK 31.28 31.91 32.56 35.43 33.33 34.87 35.43 35.43 
ASHOK PRASAD 
TARUN 
43.16 41.76 41.02 41.76 41.76 45.22  45.22 
LYDIA 38.10 38.10 37.67 39.57    39.57 
JITENDRA TALUKDAR 31.35 31.26 30.79 32.05 32.79 30.79 30.79 30.79 
 
